1
|
Spring LM, Tolaney SM, Fell G, Bossuyt V, Abelman RO, Wu B, Maheswaran S, Trippa L, Comander A, Mulvey T, McLaughlin S, Ryan P, Ryan L, Abraham E, Rosenstock A, Garrido-Castro AC, Lynce F, Moy B, Isakoff SJ, Tung N, Mittendorf EA, Ellisen LW, Bardia A. Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial. Ann Oncol 2024; 35:293-301. [PMID: 38092228 DOI: 10.1016/j.annonc.2023.11.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2023] [Revised: 11/22/2023] [Accepted: 11/30/2023] [Indexed: 01/13/2024] Open
Abstract
BACKGROUND Sacituzumab govitecan (SG), a novel antibody-drug conjugate (ADC) targeting TROP2, is approved for pre-treated metastatic triple-negative breast cancer (mTNBC). We conducted an investigator-initiated clinical trial evaluating neoadjuvant (NA) SG (NCT04230109), and report primary results. PATIENTS AND METHODS Participants with early-stage TNBC received NA SG for four cycles. The primary objective was to assess pathological complete response (pCR) rate in breast and lymph nodes (ypT0/isN0) to SG. Secondary objectives included overall response rate (ORR), safety, event-free survival (EFS), and predictive biomarkers. A response-guided approach was utilized, and subsequent systemic therapy decisions were at the discretion of the treating physician. RESULTS From July 2020 to August 2021, 50 participants were enrolled (median age = 48.5 years; 13 clinical stage I disease, 26 stage II, 11 stage III). Forty-nine (98%) completed four cycles of SG. Overall, the pCR rate with SG alone was 30% [n = 15, 95% confidence interval (CI) 18% to 45%]. The ORR per RECIST V1.1 after SG alone was 64% (n = 32/50, 95% CI 77% to 98%). Higher Ki-67 and tumor-infiltrating lymphocytes (TILs) were predictive of pCR to SG (P = 0.007 for Ki-67 and 0.002 for TILs), while baseline TROP2 expression was not (P = 0.440). Common adverse events were nausea (82%), fatigue (76%), alopecia (76%), neutropenia (44%), and rash (48%). With a median follow-up time of 18.9 months (95% CI 16.3-21.9 months), the 2-year EFS for all participants was 95%. Among participants with a pCR with SG (n = 15), the 2-year EFS was 100%. CONCLUSIONS In the first NA trial with an ADC in localized TNBC, SG demonstrated single-agent efficacy and feasibility of response-guided escalation/de-escalation. Further research on optimal duration of SG as well as NA combination strategies, including immunotherapy, are needed.
Collapse
Affiliation(s)
- L M Spring
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - S M Tolaney
- Dana-Farber Cancer Institute, Harvard Medical School, Boston
| | - G Fell
- Dana-Farber Cancer Institute, Harvard Medical School, Boston
| | - V Bossuyt
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - R O Abelman
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - B Wu
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - S Maheswaran
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - L Trippa
- Dana-Farber Cancer Institute, Harvard Medical School, Boston
| | - A Comander
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - T Mulvey
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - S McLaughlin
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - P Ryan
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - L Ryan
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - E Abraham
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - A Rosenstock
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | | | - F Lynce
- Dana-Farber Cancer Institute, Harvard Medical School, Boston
| | - B Moy
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - S J Isakoff
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - N Tung
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston
| | - E A Mittendorf
- Brigham and Women's Hospital, Harvard Medical School, Boston
| | - L W Ellisen
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston; Ludwig Center, Harvard Medical School, Boston, USA
| | - A Bardia
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.
| |
Collapse
|
2
|
Villacampa G, Tung NM, Pernas S, Paré L, Bueno-Muiño C, Echavarría I, López-Tarruella S, Roche-Molina M, Del Monte-Millán M, Marín-Aguilera M, Brasó-Maristany F, Waks AG, Pascual T, Martínez-Sáez O, Vivancos A, Conte PF, Guarneri V, Vittoria Dieci M, Griguolo G, Cortés J, Llombart-Cussac A, Muñoz M, Vidal M, Adamo B, Wolff AC, DeMichele A, Villagrasa P, Parker JS, Perou CM, Fernandez-Martinez A, Carey LA, Mittendorf EA, Martín M, Prat A, Tolaney SM. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer. Ann Oncol 2023; 34:783-795. [PMID: 37302750 PMCID: PMC10735273 DOI: 10.1016/j.annonc.2023.05.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2023] [Revised: 05/24/2023] [Accepted: 05/25/2023] [Indexed: 06/13/2023] Open
Abstract
BACKGROUND The HER2DX genomic test predicts pathological complete response (pCR) and survival outcome in early-stage HER2-positive (HER2+) breast cancer. Here, we evaluated the association of HER2DX scores with (i) pCR according to hormone receptor status and various treatment regimens, and (ii) survival outcome according to pCR status. MATERIALS AND METHODS Seven neoadjuvant cohorts with HER2DX and clinical individual patient data were evaluated (DAPHNe, GOM-HGUGM-2018-05, CALGB-40601, ISPY-2, BiOnHER, NEOHER and PAMELA). All patients were treated with neoadjuvant trastuzumab (n = 765) in combination with pertuzumab (n = 328), lapatinib (n = 187) or without a second anti-HER2 drug (n = 250). Event-free survival (EFS) and overall survival (OS) outcomes were available in a combined series of 268 patients (i.e. NEOHER and PAMELA) with a pCR (n = 118) and without a pCR (n = 150). Cox models were adjusted to evaluate whether HER2DX can identify patients with low or high risk beyond pCR status. RESULTS HER2DX pCR score was significantly associated with pCR in all patients [odds ratio (OR) per 10-unit increase = 1.59, 95% confidence interval 1.43-1.77; area under the ROC curve = 0.75], with or without dual HER2 blockade. A statistically significant increase in pCR rate due to dual HER2 blockade over trastuzumab-only was observed in HER2DX pCR-high tumors treated with chemotherapy (OR = 2.36 (1.09-5.42). A statistically significant increase in pCR rate due to multi-agent chemotherapy over a single taxane was observed in HER2DX pCR-medium tumors treated with dual HER2 blockade (OR = 3.11, 1.54-6.49). The pCR rates in HER2DX pCR-low tumors were ≤30.0% regardless of treatment administered. After adjusting by pCR status, patients identified as HER2DX low-risk had better EFS (P < 0.001) and OS (P = 0.006) compared with patients with HER2DX high-risk. CONCLUSIONS HER2DX pCR score and risk score might help identify ideal candidates to receive neoadjuvant dual HER2 blockade in combination with a single taxane in early-stage HER2+ breast cancer.
Collapse
Affiliation(s)
- G Villacampa
- SOLTI Breast Cancer Research Group, Barcelona; Oncology Data Science, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | | | - S Pernas
- Medical Oncology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona
| | - L Paré
- Reveal Genomics, Barcelona
| | - C Bueno-Muiño
- Medical Oncology Department, Hospital Infanta Cristina (Parla), Fundación de Investigación Biomédica del H.U. Puerta de Hierro, Majadahonda, Madrid
| | - I Echavarría
- Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Madrid
| | - S López-Tarruella
- Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Madrid
| | - M Roche-Molina
- Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Madrid
| | - M Del Monte-Millán
- Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Madrid
| | | | - F Brasó-Maristany
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain
| | - A G Waks
- Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA
| | - T Pascual
- SOLTI Breast Cancer Research Group, Barcelona; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain
| | - O Martínez-Sáez
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain
| | - A Vivancos
- Cancer Genomics Group, VHIO, Barcelona, Spain
| | - P F Conte
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; Istituto Oncologico Veneto, IRCCS, Padova, Italy
| | - V Guarneri
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; Istituto Oncologico Veneto, IRCCS, Padova, Italy
| | - M Vittoria Dieci
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; Istituto Oncologico Veneto, IRCCS, Padova, Italy
| | - G Griguolo
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; Istituto Oncologico Veneto, IRCCS, Padova, Italy
| | - J Cortés
- International Breast Cancer Center, Pangaea Oncology, Quirónsalud Group, Barcelona
| | - A Llombart-Cussac
- Arnau de Vilanova Hospital, Universidad Católica de Valencia, Valencia, Spain
| | - M Muñoz
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain
| | - M Vidal
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain
| | - B Adamo
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain
| | - A C Wolff
- Department of Oncology, Johns Hopkins University School of Medicine, Baltimore
| | - A DeMichele
- Department of Oncology, University of Pennsylvania, Philadelphia
| | | | - J S Parker
- Lineberger Comprehensive Cancer Center, Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill
| | - C M Perou
- Lineberger Comprehensive Cancer Center, Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill
| | - A Fernandez-Martinez
- Lineberger Comprehensive Cancer Center, Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill
| | - L A Carey
- Lineberger Comprehensive Cancer Center, Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill
| | - E A Mittendorf
- Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, USA
| | - M Martín
- Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Madrid
| | - A Prat
- Reveal Genomics, Barcelona; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain; Institute of Oncology (IOB)-Quirón, Barcelona, Spain.
| | - S M Tolaney
- Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Institute of Oncology (IOB)-Quirón, Barcelona, Spain.
| |
Collapse
|
3
|
Tarantino P, Jin Q, Mittendorf EA, King TA, Curigliano G, Tolaney SM. Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib. Ann Oncol 2022; 33:845-847. [PMID: 35525374 DOI: 10.1016/j.annonc.2022.04.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2022] [Revised: 04/11/2022] [Accepted: 04/18/2022] [Indexed: 11/30/2022] Open
Affiliation(s)
- P Tarantino
- Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA
| | - Q Jin
- Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA
| | - E A Mittendorf
- Divison of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, USA
| | - T A King
- Divison of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, USA
| | - G Curigliano
- Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy
| | - S M Tolaney
- Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA.
| |
Collapse
|
4
|
Mittendorf E. Abstract ES5-2: Optimizing the management of early stage TNBC. Cancer Res 2022. [DOI: 10.1158/1538-7445.sabcs21-es5-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The recent approvals of the immunotherapeutic agent pembrolizumab, the antibody-drug conjugate sacituzumab govitecan and the PARP inhibitors olaparib and talazoparib for select patients with metastatic triple negative breast cancer (TNBC) have spurred interest in evaluating these and other novel agents in patients with earlier stage disease. For the last several decades, a standard approach to treating early stage TNBC was to administer neoadjuvant chemotherapy, most often an anthracycline/taxane-based regimen. Pathologic complete response (pCR) rates generally ranged 30-40%. Trials such as CALGB 40603, GeparSixto and BrighTNess demonstrated that the addition of carboplatin to an anthracycline and taxane based chemotherapy could increase the pCR rates (53-58%). At the most recent ESMO conference, the BrighTNess investigators reported that the addition of carboplatin improved event free survival (EFS) after a median follow-up of 4.5 years. For patients not experiencing a pCR, the Create-X trial showed benefit of capecitabine in the adjuvant setting.As of August 2021, there is a new standard for treating early stage TNBC. Specifically, based on the KEYNOTE-522 trial, pembrolizumab, in combination with chemotherapy, is FDA approved for this indication. KEYNOTE-522 enrolled over 1170 stage 2-3 TNBC patients and randomized them to chemotherapy +/- pembrolizumab. The most recent report showed the trial met it’s co-primary endpoints of improved pCR (63% vs 56%) and EFS (84.5% vs 76.8%) after a median follow-up of 39 months. Importantly, the benefit was regardless of the PD-L1 status of the patient’s tumor. With the approval of pembrolizumab comes a number of questions: 1) which patients should receive this regimen which is associated with immune-related toxicities, some of which are lifelong, 2) what is the optimal chemotherapy backbone, 3) is a full year of pembrolizumab required and 4) are there other biomarkers to be explored that may predict response to therapy or the development of toxicity? Other studies either have or are evaluating other targeted agents in the preoperative setting for early stage TNBC. In a small study of 20 BRCA mutation carriers treated preoperatively with single agent talazoparib, investigators reported a pCR rate of 53%. A study looking at sacituzumab monotherapy in the preoperative setting has completed accrual and the results are awaited. These two trials begin to address the question of whether we can identify an “achilles” heel in TNBC and if so, will targeting it improve patient outcomes. Good correlative studies that provide improved understanding of the impact of these therapies on the TNBC microenvironment will help inform the next generation of trials; likely combination therapies.There is also the question of adjuvant therapy, particularly for those that do not experience a pCR with preoperative therapy. As stated above, the CREATE-X trial supports the use of capecitabine in patients with residual disease, however EA1131 demonstrated that outcomes are still poor for this population. More recently, for patients with BRCA-mutated cancers, the OlympiA trial showed benefit to a year of adjuvant olaparib. There is also growing interest in whether patients with residual disease who are at highest risk for recurrence can be identified using technologies looking for cell-free DNA to find those with minimal residual disease. Historically we’ve thought about TNBC for what it’s not – it is not ER, PR or HER2 positive. With multiple studies now showing benefit of specific agents in TNBC, the next several years will provide an opportunity to more extensively dissect triple negative tumors and their. microenvironment. This will allow us to learn what TNBC “is”, and which of likely multiple different therapeutic strategies will be best applied to which patients.
Citation Format: E Mittendorf. Optimizing the management of early stage TNBC [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr ES5-2.
Collapse
Affiliation(s)
- E Mittendorf
- Dana-Farber/Brigham and Women's Cancer Center, Boston, MA
| |
Collapse
|
5
|
Mittendorf E. Abstract SP097: Local Regional Management Following Neoadjuvant Chemotherapy: Minding the Knowledge Gaps. Cancer Res 2021. [DOI: 10.1158/1538-7445.sabcs20-sp97] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Neoadjuvant chemotherapy is often used in managing breast cancer patients, particular those with HER2-positive (HER2+) or triple negative disease. Among the known benefits of administering chemotherapy prior to surgery is the opportunity to assess response which informs prognosis. The CTneoBC analysis, which included 12 trials enrolling over 11,950 patients, showed that patients experiencing a pathologic complete response (pCR; ypT0ypN0 or ypT0/isN0) have improved event-free and overall survival with the association between pCR and longterm outcomes being strongest in patients with triple negative breast cancer (TNBC) and in those with HER2+/hormone receptor-negative breast cancer receiving trastuzumab. In triple negative and HER2+ breast cancer, the response to neoadjuvant chemotherapy also informs the need for additional adjuvant therapy. For patients with TNBC and significant residual disease after neoadjuvant chemotherapy, the CREATE-X trial showed benefit for adjuvant xeloda. For patients with HER2+ breast cancer not experiencing a pCR to neoadjuvant chemotherapy plus HER2-targeted therapy, the KATHERINE trial showed a significant improvement in invasive disease-free survival and overall survival in patients receiving adjuvant T-DM1 versus adjuvant trastuzuamb. With respect to considerations for local regional therapy, it is known that neoadjuvant chemotherapy decreases the primary tumor size such that tumors thought to be inoperable become operable and tumors thought to require mastectomy downstage to be eligible for lumpectomy. More recently it has been shown that neoadjuvant chemotherapy can decrease the extent of axillary surgery required. While historically patients with clinically node positive disease at presentation were thought to require axillary lymph node dissection (ALND), the American College of Surgeons Oncology Group Z1071 trial demonstrated that sentinel lymph node biopsy (SLNB) was feasible in those who convert to clinically node negative disease following neoadjuvant chemotherapy. These findings were confirmed in the European SENTINA trial and Canadian SN-FNAC study. All three of these studies suggested that technical aspects of the SLNB procedure were critical to ensure a sufficiently low false negative rate. While these are the “known knowns”, there are many “known unknowns” and evolving data, particularly as it relates to local regional therapy following neoadjuvant chemotherapy. Included among the “known unknowns” are the optimal imaging modality to assess response to neoadjuvant chemotherapy thereby facilitating surgical planning, optimal technique for performing SLNB for those patients converting from clinical N1 to clinical N0 disease after neoadjuvant chemotherapy, the definition of negative margins for a lumpectomy, the role of routine use of immunohistochemistry for cytokeratins in pathologic evaluation of the sentinel lymph nodes, the optimal method for pathologic staging following neoadjuvant chemotherapy, and the role of ALND versus radiation therapy for patients with residual nodal metastases in the sentinel nodes. More recently, it has been questioned whether patients experiencing a complete radiographic response can undergo image guided biopsy in lieu of surgery; yet data from 3 prospective series demonstrate unacceptably high false negative rates with this approach. Given the significant implications of accurately assessing response to therapy and the presence of residual disease, optimizing local regional management is a critical component of the multidisciplinary care of these patients. In this lecture, the available data guiding local regional management after neoadjuvant chemotherapy will be reviewed with attention focused on areas in which there is limited data, therefore knowledge gaps.
Citation Format: E Mittendorf. Local Regional Management Following Neoadjuvant Chemotherapy: Minding the Knowledge Gaps [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr SP097.
Collapse
|
6
|
Saji S, Mittendorf E, Harbeck N, Zhang H, Barrios C, Hegg R, Koehler A, Sohn J, Iwata H, Telli M, Ferrario C, Punie K, Llorca FP, Patel S, Duc AN, Hermoso ML, Maiya V, Molinero L, Chui S, Jung K. 3MO IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemo in early triple-negative breast cancer (TNBC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.024] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
7
|
Emens L, Craggs C, Debiasi M, Flores-Avile C, Incerti D, Downer M, Dhillon P, Mittendorf E. 196P Neoadjuvant and adjuvant chemotherapy (NACT/ACT) treatment (tx) patterns in a real-world cohort of US pts with early triple-negative breast cancer (eTNBC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
8
|
Abuhadra N, Sun R, Litton J, Rauch G, Thompson A, Lim B, Adrada B, Mittendorf E, Damodaran S, Pitpitan R, Arun B, White J, Ravenberg E, Santiago L, Sahin A, Murthy R, Ueno N, Ibrahim N, Moulder S, Huo L. 98O The immunomodulatory (IM) signature enhances prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple negative breast cancers (TNBC) with moderate stromal tumour infiltrating lymphocytes (sTIL). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.03.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
9
|
Mittendorf E. Abstract MS1-1: Immunotherapy in breast cancer: enhancing response to checkpoint blockade. Cancer Res 2020. [DOI: 10.1158/1538-7445.sabcs19-ms1-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Historically, breast tumors have been categorized as non-immunogenic in part due to a paucity of tumor infiltrating lymphocytes (TIL) when compared to other histologies. Multiple studies have now demonstrated an endogenous immune response against breast cancer with tumors having TIL present in the tumor and surrounding stroma. The extent of TIL infiltrate is dictated by the subtype of disease being highest in triple negative breast cancer (TNBC) and lowest in hormone receptor positive, HER2 negative (HR+/HER2-) disease. Recent studies have shown that immunotherapy, in the form of immune checkpoint blockade, can be effective in treating breast cancer patients. Specifically, the IMpassion 130 trial, a phase III study that enrolled over 900 patients with metastatic TNBC and randomized them to the immune checkpoint blockade agent atezolizumab plus nab-paclitaxel versus placebo plus nab-paclitaxel, demonstrated benefit to the addition of immunotherapy with respect to progression free survival as well as overall survival; a difference that was greater in patients with PD-L1 positive disease. Based on these data, the combination of atezolizumab plus nab-paclitaxel was approved for use in patients with PD-L1+ metastatic TNBC. More recently, data from a large phase III trial evaluating the use of the immune checkpoint blockade agent pembrolizumab in the neoadjuvant setting for TNBC patients showed a significant improvement in the rates of pathologic complete response. Based in part on these successes, there is significant enthusiasm for using immunotherapy to treat breast cancer patients. It must be recognized however, that a minority of patients respond. Additional work must therefore be done to expand the number of patients with TNBC who respond as well as to identify strategies for successfully employing immunotherapy for HER2+ and HR+ positive breast cancer. Development of these strategies requires understanding of the cancer immunity cycle and how it can be altered to enhance endogenous immune responses to breast cancer as well as improved understanding of the immune aspects of the tumor microenvironment and how standard of care therapies alter that microenvironment. As an example, there is emerging data showing that PARP inhibition leads to cytoplasmic DNA which activates the STING pathway leading to increased expression of release of type 1 interferons, increased MHC expression and antigen presentation and increased infiltration of effector T cells. Ongoing trials are therefore evaluating those agents in combination with immunotherapy. Our lab has shown that PARP inhibition further modifies the tumor microenvironment suggesting additional therapeutic targets. In addition, there is mounting evidence regarding potential mechanisms behind why some subtypes of breast cancer mount a robust immune response while others remain immunologically “cold”. Differences in antigen processing and presentation likely contribute and understanding how HR+ tumors “hide” from immune recognition could contribute to developing strategies to make these tumors susceptible to immunotherapy. Finally, our group has recently published data demonstrating a difference in susceptibility to immune checkpoint blockade based on age suggesting that a patient’s systemic immune status could predict therapeutic response and potentially be manipulated to enhance that response.
Citation Format: E Mittendorf. Immunotherapy in breast cancer: enhancing response to checkpoint blockade [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr MS1-1.
Collapse
Affiliation(s)
- E Mittendorf
- Dana-Farber/ Brigham and Womens Cancer Center, Boston, MA
| |
Collapse
|
10
|
Barroso-Sousa R, Barry WT, Guo H, Dillon D, Tan YB, Fuhrman K, Osmani W, Getz A, Baltay M, Dang C, Yardley D, Moy B, Marcom PK, Mittendorf EA, Krop IE, Winer EP, Tolaney SM. The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial. Ann Oncol 2019; 30:575-581. [PMID: 30753274 PMCID: PMC8033534 DOI: 10.1093/annonc/mdz047] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
BACKGROUND Previous data suggest that the immune microenvironment plays a critical role in human epidermal growth factor receptor 2 (HER2) -positive breast cancer; however, there is little known about the immune profiles of small HER2-positive tumors. In this study, we aimed to characterize the immune microenvironment of small HER2-positive breast cancers included in the Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer (APT) trial and to correlate the immune markers with pathological and molecular tumor characteristics. PATIENTS AND METHODS The APT trial was a multicenter, single-arm, phase II study of paclitaxel and trastuzumab in patients with node-negative HER2-positive breast cancer. The study included 406 patients with HER2-positive, node-negative breast cancer, measuring up to 3 cm. Exploratory analysis of tumor infiltrating lymphocytes (TIL), programmed death-ligand 1 (PD-L1) expression (by immunohistochemistry), and immune gene signatures using data generated by nCounter PanCancer Pathways Panel (NanoString Technologies, Seattle, WA), and their association with pathological and molecular characteristics was carried out. RESULTS Of the 406 patients, 328 (81%) had at least one immune assay carried out: 284 cases were evaluated for TIL, 266 for PD-L1, and 213 for immune gene signatures. High TIL (≥60%) were seen with greater frequency in hormone-receptor (HR) negative, histological grades 2 and 3, as well in HER2-enriched and basal-like tumors. Lower stromal PD-L1 (≤1%) expression was seen with greater frequency in HR-positive, histological grade 1, and in luminal tumors. Both TIL and stromal PD-L1 were positively correlated with 10 immune cell signatures, including Th1 and B cell signatures. Luminal B tumors were negatively correlated with those signatures. Significant correlation was seen among these immune markers; however, the magnitude of correlation did not indicate a monotonic relationship between them. CONCLUSION Immune profiles of small HER2-positive breast cancers differ according to HR status, histological grade, and molecular subtype. Further work is needed to explore the implication of these findings on disease outcome. CLINICAL TRIAL REGISTRATION clinicaltrials.gov identifier: NCT00542451.
Collapse
Affiliation(s)
| | - W T Barry
- Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston
| | - H Guo
- Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston
| | - D Dillon
- Department of Pathology, Brigham and Women's Hospital, Boston
| | - Y B Tan
- Department of Pathology, Brigham and Women's Hospital, Boston
| | | | | | - A Getz
- Department of Pathology, Brigham and Women's Hospital, Boston
| | - M Baltay
- Department of Pathology, Brigham and Women's Hospital, Boston
| | - C Dang
- Breast Cancer Medicine Service, Department of Medicine, Solid Tumor Division, Memorial Sloan Kettering Cancer Center, New York; Department of Medicine, Weill Cornell Medical Center, New York
| | | | - B Moy
- Department of Hematology-Oncology, Massachusetts General Hospital, Boston
| | - P K Marcom
- Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Durham
| | - E A Mittendorf
- Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, USA
| | | | | | | |
Collapse
|
11
|
Pernas S, Goel S, Harrison BT, Hu J, Johnson N, Regan M, Chichester LA, Nakhlis F, Schlosnagle EJ, Winship G, Guerriero JL, Parsons H, Mittendorf EA, Overmoyer B. Abstract PD3-08: Assessment of the tumor immune environment in inflammatory breast cancer treated with neoadjuvant dual-HER2 blockade. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd3-08] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Inflammatory breast cancer (IBC) is an aggressive form of breast cancer that remains relatively understudied. We examined the efficacy of neoadjuvant dual-HER2 blockade (trastuzumab (H) and pertuzumab (P)) combined with paclitaxel (T) in HER2+ IBC, including a planned analysis to elucidate associations between the tumor immune microenvironment profile and response to therapy.
Methods: An IRB-approved, single-arm phase II trial for patients (pts) with newly diagnosed HER2+ IBC was conducted. Pts had a pre-treatment biopsy of the affected breast (D1) followed by a loading dose of HP. A second biopsy was performed 1 week (wk) later (D8), when T (80mg/m2/wk x 16 wks) was added to HP. Responding pts underwent modified radical mastectomy (MRM) where residual disease was collected. The primary objective was to determine the rate of pathologic complete response (pCR) defined as ypT0/isN0. Residual Cancer Burden (RCB) was also determined. Tumor specimens from D1, D8 and MRM were assessed for disease cellularity and scored for percentage of tumor infiltrating lymphocytes (TILs): low=0-10%, intermediate=11-59%, high>60%. RNA-sequencing was performed on tumor tissue from D1 and D8 to explore the impact of short-term HP treatment on the tumor transcriptomic profile and to identify potential predictors of pCR.
Results: 23 pts with HER2+ IBC were enrolled between 8/2013-6/2017. Mean age was 48 years (range 32-74); 11 pts (48%) had estrogen and progesterone receptor (ER/PR) negative disease. Matched tumor biopsies (D1, D8) were obtained in all 23 pts; 21 underwent MRM; 1 was lost to follow-up and 1 had disease progression. In the intent to treat analysis, 10/23 (43%) pts achieved a pCR and 7 (30%) had RCB-1. Ten of the 22 evaluable pts achieved a pCR (45.5%). TILs were evaluable in 20/23 (87%) matched tumor biopsies (D1, D8). Among the D1 biopsy specimens: 19 (95%) had low levels, 2 (10%) had intermediate levels, and none had high levels. When D1 TIL levels were compared with D8 levels, 3(15%) had an increase in TILs, 16(80%) had no change in TIL levels, and 1(5%) had a decrease in the level of TILs. Both samples with intermediate levels and 2 of 3 samples with high levels of TILs on D1 and D8 were seen in ER/PR negative disease. An evaluation of biopsy specimens associated with subsequent pCR using GO enrichment analysis from the RNA-Seq data showed significant upregulation of several immune-process related gene expression signatures both at D1 and D8 (e.g. antigen processing and presentation, TCR signaling, NK cell cytotoxicity, p-value: 2.99E-48 to 1.39E-16) when compared with those associated with residual disease at the time of MRM. Across the entire cohort, D8 biopsies showed evidence of upregulated anti-tumor immunity compared to D1 biopsies (p-value: 9.57E-06 to 0.012). Notably, this change from D1 to D8 was largely restricted to tumors that achieved a pCR.
Conclusion: THP for 16 weeks was a highly effective treatment for HER2+ IBC. Immune activation as determined by gene expression signatures predicted pCR, and moreover upregulation of anti-tumor immunity after 1 wk of HP might further predict a complete pathologic response to therapy. ClinicalTrials.gov identifier: NCT01796197
Citation Format: Pernas S, Goel S, Harrison BT, Hu J, Johnson N, Regan M, Chichester LA, Nakhlis F, Schlosnagle EJ, Winship G, Guerriero JL, Parsons H, Mittendorf EA, Overmoyer B. Assessment of the tumor immune environment in inflammatory breast cancer treated with neoadjuvant dual-HER2 blockade [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD3-08.
Collapse
Affiliation(s)
- S Pernas
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | - S Goel
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | - BT Harrison
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | - J Hu
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | - N Johnson
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | - M Regan
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | - LA Chichester
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | - F Nakhlis
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | - EJ Schlosnagle
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | - G Winship
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | - JL Guerriero
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | - H Parsons
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | - EA Mittendorf
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | - B Overmoyer
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| |
Collapse
|
12
|
Lucci A, Hall C, Hess K, Ravenberg E, Clayborn A, Mittendorf E, Rauch G, Candelaria R, Moulder S, Thompson A. Abstract P3-01-01: Circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-01-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: ARTEMIS (A Randomized, TNBC Enrolling trial to confirm Molecular profiling Improves Survival) is a randomized trial to determine if precision guided neoadjuvant chemotherapy (NAC) impacts rates of pathologic complete response in the breast and axillary nodes (pCR). We hypothesized that CTCs in peripheral blood after completion of NAC would provide prognostic information beyond pCR alone in TNBC patients.
Methods: Blood was assessed for CTCs after NAC as part of two IRB approved studies, ARTEMIS (2014 – 0185/PA15-1050), and LAB04-0698. CTCs were identified using the Cell Search® System (Menarini Silicon Biosystems). Samples with one or more cells, also having morphologic criteria for malignancy, were deemed CTC positive. Log-rank test and Cox regression analysis were applied to evaluate associations between CTC positive, pCR, and overall survival.
Results: pCR was achieved in 24/68 (35%) patients with TNBC. Twenty four patients (35%) were CTC positive. Three year overall survival was evaluated in 4 groups of patients: pCR and no CTCs (n=20), pCR and CTC positive (n=4), non-pCR and no CTCs (n=24) and non-pCR and CTC positive (n=20). Three year overall survival was higher in the pCR and no CTCs cohort (100%), compared to pCR and CTC positive (50%), non-pCR and no CTCs (83%), non-pCR and CTC positive (19%); log rank p<0.0001. In the non-pCR and CTC positive patient cohorts, the presence of CTCs was associated with significant risk of death at 3 years [hazard ratio of 12.3 (95% CI 3.4-454, p=0.00002)], whereas a favorable, but non-significant trend was noted for pCR [hazard ratio of 0.2 (95% CI 0.0, 1.4, p=0.11)].
Conclusion: The identification of CTCs after NAC has prognostic significance beyond that of pCR, and should be considered in evaluation of patients for clinical trials of adjuvant therapies.
Citation Format: Lucci A, Hall C, Hess K, Ravenberg E, Clayborn A, Mittendorf E, Rauch G, Candelaria R, Moulder S, Thompson A. Circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-01-01.
Collapse
Affiliation(s)
- A Lucci
- University of Texas MD Anderson Cancer Center, Houston, TX; Dana Farber Cancer Institute, Boston, MA
| | - C Hall
- University of Texas MD Anderson Cancer Center, Houston, TX; Dana Farber Cancer Institute, Boston, MA
| | - K Hess
- University of Texas MD Anderson Cancer Center, Houston, TX; Dana Farber Cancer Institute, Boston, MA
| | - E Ravenberg
- University of Texas MD Anderson Cancer Center, Houston, TX; Dana Farber Cancer Institute, Boston, MA
| | - A Clayborn
- University of Texas MD Anderson Cancer Center, Houston, TX; Dana Farber Cancer Institute, Boston, MA
| | - E Mittendorf
- University of Texas MD Anderson Cancer Center, Houston, TX; Dana Farber Cancer Institute, Boston, MA
| | - G Rauch
- University of Texas MD Anderson Cancer Center, Houston, TX; Dana Farber Cancer Institute, Boston, MA
| | - R Candelaria
- University of Texas MD Anderson Cancer Center, Houston, TX; Dana Farber Cancer Institute, Boston, MA
| | - S Moulder
- University of Texas MD Anderson Cancer Center, Houston, TX; Dana Farber Cancer Institute, Boston, MA
| | - A Thompson
- University of Texas MD Anderson Cancer Center, Houston, TX; Dana Farber Cancer Institute, Boston, MA
| |
Collapse
|
13
|
Garrido-Castro AC, Hughes ME, Cherniack A, Barroso-Sousa R, Bychkovsky BL, Di Lascio S, Berger A, Mittendorf EA, Files JL, Guo H, Kumari P, Cerami E, Krop IE, Wagle N, Lindeman NI, MacConaill LE, Dillon DA, Winer EP, Lin NU. Abstract PD9-01: Genomic alterations associated with loss of HR expression in metastatic breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd9-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Discordance in hormone receptor (HR) status between primary (p) tumors and metastatic (m) recurrences has been widely described. Loss of estrogen and progesterone receptor expression occurs in ˜12% of asynchronous recurrences, leading to triple-negative (TN) status in the metastasis. Genomic mechanisms driving HR loss and its prognostic and therapeutic implications have not been fully elucidated.
Methods: Targeted NGS (Oncopanel, OP) at Dana-Farber Cancer Institute using multiplexed copy number variation and mutation (mut) detection across the full coding regions of 300 genes and selected intronic regions of 35 genes was prospectively performed on either archival primary or metastatic samples collected in patients (pts) with metastatic breast cancer (MBC). Receptor status at initial diagnosis and recurrence were reviewed using a 1% cutoff to define HR-positivity and excluding HER2+ cases. Fisher´s exact test was used to compare frequency of alterations. Tumor mut burden (TMB) was computed normalizing the sum of reported exon mut in each pt by the exonic-bait-set size of the panel.
Results: Between 8/2013-9/2016, 929 pts with MBC underwent OP testing. Of 517 pts diagnosed with primary HR+/HER2- breast cancer, at time of recurrence 388 remained HR+/HER2- (pHR+/mHR+), 39 switched to HR-/HER2- (pHR+/mTN, of which 23 (59%) had initial HR expression >10%), 10 switched to HER2+ and 80 had unknown metastatic receptor status. Comparison between primary samples in pHR+/mHR+ (n=245) and pHR+/mTN (n=24) showed that pHR+/mTN was significantly more likely to harbor mut in TP53, STK11 and MSH6, amplifications (amp) in CCNE1 and FGFR2, and less likely to have PIK3CA mut or CCND1 amp. Median TMB in primary pHR+/mHR+ was 6.05 mut/Mb (0-37.5) and 5.68 mut/Mb (1.2-10.9) in pHR+/mTN (p=0.45). Metastatic samples in pHR+/mTN (n=15) were enriched in ARID1A, CRTC2 and CDH1 mut compared to metastases (n=40) in pts who remained TN (pTN/mTN). Deletions in CDKN2A/2B and RB1, and mut in TP53, NOTCH2 and ERCC2 were more prevalent in recurrent tumors of pHR+/mTN than pHR+/mHR+. In metastases, TMB was higher in pHR+/mTN than pTN/mTN or pHR+/mHR+ (10.9 vs. 7.0 vs. 7.3 mut/Mb, respectively; p=0.002). Median OS from initial diagnosis was 9.4 yrs in pHR+/mTN, less than pHR+/mHR+ (15.9 yrs; p=0.009) and greater than pTN/mTN (4.3 yrs; p=0.008). Median OS from MBC diagnosis was 1.8 yrs in pHR+/mTN, less than pHR+/mHR+ (6.4 yrs; p=0.001) but not significantly different than pTN/mTN (1.5 yrs, p=0.3).
pHR+/mHR+ (n=245)pHR+/mTN (n=24)p value NFreq (%)NFreq (%) MutTP536325.72083.3<0.00001PIK3CA9438.4000GATA33514.3000.053STK1152.0312.50.026MSH641.6312.50.017AmpFGFR20028.30.008CCNE10028.30.008CCND14418.0000.018
Conclusion: Targeted NGS shows that alterations in DNA damage and cell-cycle regulation pathways in primary HR+ tumors are associated with HR loss in the metastatic setting. Primary tumors that lose HR appear more similar to basal-like than luminal tumors, despite >10% baseline HR expression in most pts, and once metastatic, survival is comparable to pTN/mTN. Metastases with HR loss have higher TMB than those that remain HR+ or TN throughout the course of the disease. These findings, if confirmed, may influence treatment and pt selection for clinical trials.
Citation Format: Garrido-Castro AC, Hughes ME, Cherniack A, Barroso-Sousa R, Bychkovsky BL, Di Lascio S, Berger A, Mittendorf EA, Files JL, Guo H, Kumari P, Cerami E, Krop IE, Wagle N, Lindeman NI, MacConaill LE, Dillon DA, Winer EP, Lin NU. Genomic alterations associated with loss of HR expression in metastatic breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD9-01.
Collapse
Affiliation(s)
- AC Garrido-Castro
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - ME Hughes
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - A Cherniack
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - R Barroso-Sousa
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - BL Bychkovsky
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - S Di Lascio
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - A Berger
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - EA Mittendorf
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - JL Files
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - H Guo
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - P Kumari
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - E Cerami
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - IE Krop
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - N Wagle
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - NI Lindeman
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - LE MacConaill
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - DA Dillon
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - EP Winer
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - NU Lin
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| |
Collapse
|
14
|
Barroso-Sousa R, Tyekucheva S, Pernas-Simon S, Exman P, Jain E, Garrido-Castro AC, Hughes M, Bychkovsky B, Di Lascio S, Umeton R, Files J, Lindeman NI, MacConaill LE, Hodi FS, Krop IE, Dillon D, Winer EP, Wagle N, Lin NU, Mittendorf EA, Tolaney SM. Abstract P5-12-02: PTEN alterations and tumor mutational burden (TMB) as potential predictors of resistance or response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-12-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: To date no biomarker has been identified that predicts response to ICI in mTNBC. This study aimed to explore if tumor genomic alterations correlate with efficacy of PD-1/PD-L1 inhibition in patients (pts) with mTNBC. Methods: Demographic, treatment response, and long-term outcome data were collected on patients with mTNBC treated at Dana-Farber Cancer Institute (DFCI) under several clinical trials incorporating PD-1/PD-L1 inhibitors, given as monotherapy or combined with chemotherapy (CT). Pts included in this analysis had available results of targeted exon sequencing performed using Oncopanel, our institutional gene sequencing panel, on archival tumor tissue. TMB was calculated by determining the number of non-synonymous somatic mutations that occur per megabase of exonic sequence data across all genes on the panel. High TMB was defined as 310 mutations/megabase. TMB and gene alterations were correlated with objective response rate (ORR) per RECIST 1.1, progression-free (PFS) and overall survival (OS). Results: A total of 50 pts with mTNBC were included in this analysis. At baseline, the median age was 55.9 years (31.8–75.9), 60% had ECOG 0 and 40% had ECOG 1, 72% had visceral metastasis, and 46% had received 31 prior lines of systemic therapy in the metastatic setting. While 26% of pts received monotherapy [pembrolizumab (n=7, NCT02447003); atezolizumab (n=6; NCT01375842)], 74% received combination with CT [pembrolizumab plus eribulin (n=31; NCT02513472); atezolizumab plus nab-paclitaxel (n=6; NCT01633970)]. PTEN alterations were present in 30% of pts (mutations = 7; one copy number loss = 7; two copy number loss = 1). Median follow-up was 14 months (1–40). Pts with tumors harboring PTEN alterations had lower ORR (7% vs 57%; P<0.001), shorter median PFS (2.3 vs 6.3 months; P=0.027), and shorter median OS (8.1 vs 20.1 months; P=0.012) compared to pts without PTEN alterations. The median TMB was 6.6 mut/Mb (1.2–50.8), and 23% of pts had a high TMB. While high TMB was not associated with higher ORR (P=0.56), it was associated with better median PFS (16.5 vs 2.4 months; P=0.017), and better median OS (not reached vs 13.5 months; P=0.026). Both PTEN status and TMB remained significantly associated with PFS in the multivariable model. Only PTEN status remained significantly associated with OS in the multivariable analysis with the same covariables. Ongoing analysis to better understand if these predictors are specific for predicting benefit to immunotherapy and/or a marker of chemotherapy resistance will be presented at the symposium. Conclusion: PTEN genomic alterations and TMB may impact benefit from PD-1/PD-L1 inhibitors largely administered with chemotherapy in mTNBC. These observations warrant prospective validation and may inform the importance of stratifying pts according to these characteristics in future randomized studies with ICI.
Table 1.Multivariable analysis for PFS Hazard ratioConfidence Intervalp-valueCombination therapy0.420.16 – 1.130.009Visceral metastasis1.310.63 – 2.770.46Previous lines of therapy1.020.09 – 0.700.85ECOG 12.11.06 – 1.280.034PTEN altered3.741.65 – 8.440.002Hypermutated tumors0.850.75 – 0.970.011
Citation Format: Barroso-Sousa R, Tyekucheva S, Pernas-Simon S, Exman P, Jain E, Garrido-Castro AC, Hughes M, Bychkovsky B, Di Lascio S, Umeton R, Files J, Lindeman NI, MacConaill LE, Hodi FS, Krop IE, Dillon D, Winer EP, Wagle N, Lin NU, Mittendorf EA, Tolaney SM. PTEN alterations and tumor mutational burden (TMB) as potential predictors of resistance or response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-12-02.
Collapse
Affiliation(s)
- R Barroso-Sousa
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - S Tyekucheva
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - S Pernas-Simon
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - P Exman
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - E Jain
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - AC Garrido-Castro
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - M Hughes
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - B Bychkovsky
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - S Di Lascio
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - R Umeton
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - J Files
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - NI Lindeman
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - LE MacConaill
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - FS Hodi
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - IE Krop
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - D Dillon
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - EP Winer
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - N Wagle
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - NU Lin
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - EA Mittendorf
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - SM Tolaney
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| |
Collapse
|
15
|
Clifton GT, Kemp Bohan PM, Hale DF, Myers JW, Brown TA, Holmes JP, Vreeland TJ, Litton JK, Murthy RK, Mittendorf EA, Peoples GE. Abstract P2-09-01: Subgroups analysis of a multicenter, prospective, randomized, blinded phase 2b trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for prevention of recurrence in breast cancer patients. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-09-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:HER2 low-expressing (LE) (IHC 1-2+, FISH non-amplified) breast cancer (BC) patients (pts) have not benefited from HER2-directed therapy despite HER2 antigen availability. Triple negative BC (TNBC), in particular, is immunogenic and in need of additional therapeutic options. We have previously shown the HER2-derived nelipeptimut-S (E75) + GM-CSF (NeuVax) to be synergistic with trastuzumab (Tz) in pre-clinical and pilot clinical studies. In a planned interim analysis of a multi-center, prospective, randomized, single-blinded, placebo-controlled phase 2b trial of Tz + NeuVax vs Tz to reduce recurrence in HER2 LE, node-positive (NP) and/or triple negative BC (TNBC) pts, we previously reported that the NeuVax + Tz was safe without added cardiac toxicity and demonstrated a significant reduction of recurrences in TNBC pts. This analysis examines additional subsets in this trial.
Methods:HER2 LE, NP and/or TNBC pts who were clinically disease-free after standard therapy were randomized to receive Tz+NeuVax (vaccine group; VG) or Tz+GM-CSF (control group; CG). All pts received 1 yr of Tz per label. NeuVax or GM-CSF was given every 3 weeks x 6 starting with the 3rdTz dose, and then boosted every 6 months x 4. This pre-specified interim analysis was triggered 6 months after last enrollment. The primary endpoint is intention-to-treat 24 month disease-free survival (DFS) evaluated by log rank.
Results: Of 275 pts randomized in the study (VG n=136, CG n=139), 98 had TNBC (VG=53, CG=45). In the interim analysis, estimated disease-free survival (DFS) was assessed with a median follow up of 18.8 months. No significant clinicopathologic differences were seen between treatment groups. In the TNBC group, estimated DFS was higher overall in VG vs CG (91.9% v 69.9%, p=0.023; hazard ratio [HR] 0.29, 95% confidence interval [CI] 0.09-0.90). On TNBC subgroup analysis, estimated DFS was higher in VG vs CG among pts who received neoadjuvant chemotherapy (VG n=35, CG n=31; HR 0.26, CI 0.07-0.93; p=0.03), HER2 IHC 1+ BC (VG n=34, CG n=28; HR 0.20, CI 0.04-0.96; p=0.03), pts who were AJCC 7thedition stage I/II (VG n=37, CG n=27; HR incalculable, no recurrences in the VG, p=0.008), and pts 351yr of age (VG n=32 & CG n = 26; HR 0.26 CI 0.07,0.94; p=0.009). HRs did not appreciably vary based on the histologic grade or presence of lymphovascular invasion.
Conclusion:Examining the subgroups from the pre-specified interim analysis demonstrates a highly significant clinical benefit in TNBC pts overall. Within the TNBC cohort, specific benefit was seen in pts who received chemotherapy neoadjuvantly, expressed lower HER2, were earlier stage, and were older in age. These factors may help enrich the TNBC population targeted in a definitive Phase 3 study in TNBC patients with residual disease after neoadjuvant chemotherapy.
Citation Format: Clifton GT, Kemp Bohan PM, Hale DF, Myers JW, Brown TA, Holmes JP, Vreeland TJ, Litton JK, Murthy RK, Mittendorf EA, Peoples GE. Subgroups analysis of a multicenter, prospective, randomized, blinded phase 2b trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for prevention of recurrence in breast cancer patients [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-09-01.
Collapse
Affiliation(s)
- GT Clifton
- Brooke Army Medical Center, Fort Sam Houston, TX; St. Joseph Hospital, Santa Rosa, CA; MD Anderson Cancer Center, Houston, TX; Brigham and Women's Hospital, Boston, MA; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - PM Kemp Bohan
- Brooke Army Medical Center, Fort Sam Houston, TX; St. Joseph Hospital, Santa Rosa, CA; MD Anderson Cancer Center, Houston, TX; Brigham and Women's Hospital, Boston, MA; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - DF Hale
- Brooke Army Medical Center, Fort Sam Houston, TX; St. Joseph Hospital, Santa Rosa, CA; MD Anderson Cancer Center, Houston, TX; Brigham and Women's Hospital, Boston, MA; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - JW Myers
- Brooke Army Medical Center, Fort Sam Houston, TX; St. Joseph Hospital, Santa Rosa, CA; MD Anderson Cancer Center, Houston, TX; Brigham and Women's Hospital, Boston, MA; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - TA Brown
- Brooke Army Medical Center, Fort Sam Houston, TX; St. Joseph Hospital, Santa Rosa, CA; MD Anderson Cancer Center, Houston, TX; Brigham and Women's Hospital, Boston, MA; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - JP Holmes
- Brooke Army Medical Center, Fort Sam Houston, TX; St. Joseph Hospital, Santa Rosa, CA; MD Anderson Cancer Center, Houston, TX; Brigham and Women's Hospital, Boston, MA; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - TJ Vreeland
- Brooke Army Medical Center, Fort Sam Houston, TX; St. Joseph Hospital, Santa Rosa, CA; MD Anderson Cancer Center, Houston, TX; Brigham and Women's Hospital, Boston, MA; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - JK Litton
- Brooke Army Medical Center, Fort Sam Houston, TX; St. Joseph Hospital, Santa Rosa, CA; MD Anderson Cancer Center, Houston, TX; Brigham and Women's Hospital, Boston, MA; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - RK Murthy
- Brooke Army Medical Center, Fort Sam Houston, TX; St. Joseph Hospital, Santa Rosa, CA; MD Anderson Cancer Center, Houston, TX; Brigham and Women's Hospital, Boston, MA; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - EA Mittendorf
- Brooke Army Medical Center, Fort Sam Houston, TX; St. Joseph Hospital, Santa Rosa, CA; MD Anderson Cancer Center, Houston, TX; Brigham and Women's Hospital, Boston, MA; Uniformed Services University of the Health Sciences, Bethesda, MD
| | - GE Peoples
- Brooke Army Medical Center, Fort Sam Houston, TX; St. Joseph Hospital, Santa Rosa, CA; MD Anderson Cancer Center, Houston, TX; Brigham and Women's Hospital, Boston, MA; Uniformed Services University of the Health Sciences, Bethesda, MD
| |
Collapse
|
16
|
Murthy RK, Raghavendra AS, Hess KR, Barcenas CH, Lim B, Moulder SL, Giordano SH, Mittendorf EA, Thompson A, Ueno NT, Valero V, Litton JK, Tripathy D, Chavez-Macgregor M. Abstract P6-17-04: 3-year relapse-free survival of stage II-III HER2-neu positive breast cancer treated with pertuzumab and trastuzumab-containing neoadjuvant therapy compared to trastuzumab-containing therapy. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-17-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Pertuzumab (P) in combination with trastuzumab (H) based chemotherapy is FDA-approved as a standard neoadjuvant treatment for patients with clinical stage II-III HER2-positive (HER2+) breast cancer (BC). The goal of this study was to evaluate the pathologic complete response (pCR) rate for neoadjuvant HP-containing regimens compared to H-containing regimens and report the 3-year relapse-free survival (RFS) for patients who had a pCR compared to those with residual disease (RD).
Methods: All patients with stage II-III non-inflammatory HER2+ BC who received neoadjuvant H-containing or HP-containing therapy and underwent definitive breast and axillary surgery were identified from 2005 to 2016 through an institutional database. Medical records were examined for patient demographics, breast cancer stage, pathology results, surgical outcomes, and treatment details. pCR was defined as ypT0/is, ypN0. RFS was defined as the interval from surgery to date of last followup or death from any cause. Descriptive statistics, Cox proportional hazards, and Kaplan-Meier estimates were used for statistical analysis.
Results: Patient characteristics and results by pCR or RD status are shown in the table below. The median age was 51 (22-84) years for the HP group and 50 (21-87) years for the H group. The median follow-up time was 1.9 (0-4.2) years for the HP group and 5.3 (0.1-12) years for the H group. For the HP group, the 3-year RFS was 98% (95% CI: 95, 100) for the pCR group and 90% (95% CI: 83, 97) for the RD group; HR 0.17 (0.04, 0.82), p=0.012. For the H group, the 3-year RFS was 91% (95% CI: 88,94) for the pCR group and 75% (95% CI: 71-79) for the RD group; HR 0.31 (0.22, 0.44), p<0.0001. Among the 520 patients who achieved pCR and the 502 patients who had RD, the effect of HP vs. H was statistically significant (pCR: HR 0.24 (0.06, 1.00); p=0.015) (no pCR: HR 0.46 (0.22, 0.94); p=0.017).
Conclusion: Patients who achieve pCR have an improved 3-year RFS compared to patients who have RD. Treatment with HP-containing neoadjuvant regimens is associated with a high 3-year RFS.
VariableHP (n=215)H (n=807) pCR n=121RD n=94pCR n=399RD n= 408Age at Diagnosis<5043%46%46%51% ≥5057%54%54%49%Menopausal StatusPremenopausal46%50%53%57% Postmenopausal54%50%47%43%Clinical Stage at DiagnosisIIA40%29%34%29% IIB29%31%23%28% IIIA14%15%17%16% IIIB0%5%5%9% IIIC17%20%21%18%Clinical Nodal StatusNode (+)63%76%69%73% Node (-)37%24%31%27%Nuclear Grade1II25%32%22%28% III75%65%78%72%HR statusHR(+)52%74%52%67% HR(-)48%26%48%33%Adjuvant therapyTrastuzumab88%80%100%100% Trastuzumab and Pertuzumab3%5%0%0% Unknown9%15%20%0%11 patient in the HP pCR group had nuclear grade 1; 2 patients in the HP RD group had nuclear grade 1 tumors 2 2 patients received adjuvant TDM-1 on the NSABP B50 protocol
Citation Format: Murthy RK, Raghavendra AS, Hess KR, Barcenas CH, Lim B, Moulder SL, Giordano SH, Mittendorf EA, Thompson A, Ueno NT, Valero V, Litton JK, Tripathy D, Chavez-Macgregor M. 3-year relapse-free survival of stage II-III HER2-neu positive breast cancer treated with pertuzumab and trastuzumab-containing neoadjuvant therapy compared to trastuzumab-containing therapy [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-04.
Collapse
Affiliation(s)
- RK Murthy
- University of Texas MD Anderson Cancer Center, Houston, TX; Dana Farber/Brigham and Women's Cancer Center, Boston, MA
| | - AS Raghavendra
- University of Texas MD Anderson Cancer Center, Houston, TX; Dana Farber/Brigham and Women's Cancer Center, Boston, MA
| | - KR Hess
- University of Texas MD Anderson Cancer Center, Houston, TX; Dana Farber/Brigham and Women's Cancer Center, Boston, MA
| | - CH Barcenas
- University of Texas MD Anderson Cancer Center, Houston, TX; Dana Farber/Brigham and Women's Cancer Center, Boston, MA
| | - B Lim
- University of Texas MD Anderson Cancer Center, Houston, TX; Dana Farber/Brigham and Women's Cancer Center, Boston, MA
| | - SL Moulder
- University of Texas MD Anderson Cancer Center, Houston, TX; Dana Farber/Brigham and Women's Cancer Center, Boston, MA
| | - SH Giordano
- University of Texas MD Anderson Cancer Center, Houston, TX; Dana Farber/Brigham and Women's Cancer Center, Boston, MA
| | - EA Mittendorf
- University of Texas MD Anderson Cancer Center, Houston, TX; Dana Farber/Brigham and Women's Cancer Center, Boston, MA
| | - A Thompson
- University of Texas MD Anderson Cancer Center, Houston, TX; Dana Farber/Brigham and Women's Cancer Center, Boston, MA
| | - NT Ueno
- University of Texas MD Anderson Cancer Center, Houston, TX; Dana Farber/Brigham and Women's Cancer Center, Boston, MA
| | - V Valero
- University of Texas MD Anderson Cancer Center, Houston, TX; Dana Farber/Brigham and Women's Cancer Center, Boston, MA
| | - JK Litton
- University of Texas MD Anderson Cancer Center, Houston, TX; Dana Farber/Brigham and Women's Cancer Center, Boston, MA
| | - D Tripathy
- University of Texas MD Anderson Cancer Center, Houston, TX; Dana Farber/Brigham and Women's Cancer Center, Boston, MA
| | - M Chavez-Macgregor
- University of Texas MD Anderson Cancer Center, Houston, TX; Dana Farber/Brigham and Women's Cancer Center, Boston, MA
| |
Collapse
|
17
|
Tevis SE, Bassett R, Bedrosian I, Barcenas CH, Black DM, Caudle AS, DeSnyder SM, Fitzsullivan E, Hunt KK, Kuerer HM, Lucci A, Meric-Bernstam F, Mittendorf EA, Park K, Teshome M, Thompson AM, Hwang RF. OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer Patients. Ann Surg Oncol 2018; 26:815-820. [PMID: 30556120 DOI: 10.1245/s10434-018-7059-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2018] [Indexed: 01/26/2023]
Abstract
BACKGROUND OncotypeDX recurrence score (RS)® has been found to predict recurrence and disease-free survival in patients with node negative breast cancer. Whether RS is useful in guiding locoregional therapy decisions is unclear. We sought to evaluate the relationship between RS and lymph node burden. METHODS Patients with invasive breast cancer who underwent sentinel lymph node dissection from 2010 to 2015 were identified from a prospectively maintained database. Patients were excluded if they were clinically node positive or if they received neoadjuvant chemotherapy. RS was classified as low (< 18), intermediate (18-30), or high (> 30). The association between RS, lymph node burden, and disease recurrence was evaluated. Statistical analyses were performed in R version 3.4.0; p < 0.05 was considered significant. RESULTS A positive SLN was found in 168 (15%) of 1121 patients. Completion axillary lymph node dissection was performed in 84 (50%) of SLN-positive patients. The remaining 84 (50%) patients had one to two positive SLNs and did not undergo further axillary surgery. RS was low in 58.5%, intermediate in 32.6%, and high in 8.9%. RS was not associated with a positive SLN, number of positive nodes, maximum node metastasis size, or extranodal extension. The median follow-up was 23 months. High RS was not associated with locoregional recurrence (p = 0.07) but was significantly associated with distant recurrence (p = 0.0015). CONCLUSIONS OncotypeDX RS is not associated with nodal burden in women with clinically node-negative breast cancer, suggesting that RS is not useful to guide decisions regarding extent of axillary surgery for these patients.
Collapse
Affiliation(s)
- S E Tevis
- Department of Surgery, University of Colorado, Aurora, CO, USA
| | - R Bassett
- Department of Biostatistics, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - I Bedrosian
- Department of Breast Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - C H Barcenas
- Department of Breast Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - D M Black
- Department of Breast Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - A S Caudle
- Department of Breast Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - S M DeSnyder
- Department of Breast Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - E Fitzsullivan
- Department of Breast Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - K K Hunt
- Department of Breast Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - H M Kuerer
- Department of Breast Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - A Lucci
- Department of Breast Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - F Meric-Bernstam
- Department of Breast Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - E A Mittendorf
- Department of Surgery, Brigham and Women's Hospital, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA
| | - K Park
- Department of Breast Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - M Teshome
- Department of Breast Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - A M Thompson
- Department of Breast Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - R F Hwang
- Department of Breast Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
| |
Collapse
|
18
|
Tevis SE, Neuman HB, Mittendorf EA, Kuerer HM, Bedrosian I, DeSnyder SM, Thompson AM, Black DM, Scoggins ME, Sahin AA, Hunt KK, Caudle AS. Multidisciplinary Intraoperative Assessment of Breast Specimens Reduces Number of Positive Margins. Ann Surg Oncol 2018; 25:2932-2938. [PMID: 29947001 DOI: 10.1245/s10434-018-6607-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2018] [Indexed: 11/18/2022]
Abstract
BACKGROUND Successful breast-conserving surgery requires achieving negative margins. At our institution, the whole surgical specimen is imaged and then serially sectioned with repeat imaging. A multidisciplinary discussion then determines need for excision of additional margins. The goal of this study was to determine the benefit of each component of this approach in reducing the number of positive margin. METHODS This single-institution, prospective study included ten breast surgical oncologists who were surveyed to ascertain whether they would have taken additional margins based their review of whole specimen images (WSI) and review of serially sectioned images (SSI). These results were compared with the multidisciplinary decisions (MDD) and pathology results. Margin status was defined using consensus guidelines. RESULTS One hundred surveys were completed. Margins on the original specimen were positive or close in 21%. After WSI, surgeons reported that they would have taken additional margins in 26 cases, reducing the number of positive/close margins from 21 to 13% (p < 0.001). After SSI, 52 would have taken additional margins; however, the number of positive/close margins remained 13%. MDD resulted in additional margins taken in 56 cases, reducing the number of positive/close margins to 7% (p < 0.001 compared with SSI). CONCLUSIONS While surgeon review of specimen radiographs can decrease the number of positive or close margins from 21 to 13%, more rigorous multidisciplinary, intraoperative margin assessment reduces the number of close or positive margins to 7%.
Collapse
Affiliation(s)
- S E Tevis
- Department of Breast Surgical Oncology, University of Texas- MD Anderson Cancer Center, Houston, TX, USA
| | - H B Neuman
- University of Wisconsin, Madison, WI, USA
| | - E A Mittendorf
- Department of Breast Surgical Oncology, University of Texas- MD Anderson Cancer Center, Houston, TX, USA.,Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA
| | - H M Kuerer
- Department of Breast Surgical Oncology, University of Texas- MD Anderson Cancer Center, Houston, TX, USA
| | - I Bedrosian
- Department of Breast Surgical Oncology, University of Texas- MD Anderson Cancer Center, Houston, TX, USA
| | - S M DeSnyder
- Department of Breast Surgical Oncology, University of Texas- MD Anderson Cancer Center, Houston, TX, USA
| | - A M Thompson
- Department of Breast Surgical Oncology, University of Texas- MD Anderson Cancer Center, Houston, TX, USA
| | - D M Black
- Department of Breast Surgical Oncology, University of Texas- MD Anderson Cancer Center, Houston, TX, USA
| | - M E Scoggins
- Department of Breast Surgical Oncology, University of Texas- MD Anderson Cancer Center, Houston, TX, USA
| | - A A Sahin
- Department of Breast Surgical Oncology, University of Texas- MD Anderson Cancer Center, Houston, TX, USA
| | - K K Hunt
- Department of Breast Surgical Oncology, University of Texas- MD Anderson Cancer Center, Houston, TX, USA
| | - A S Caudle
- Department of Breast Surgical Oncology, University of Texas- MD Anderson Cancer Center, Houston, TX, USA.
| |
Collapse
|
19
|
Rauch GM, Li H, Zhu H, Adrada BE, Santiago L, Candelaria RP, Wang H, Leung J, Thompson A, Litton J, Wu Y, Lim B, Moulder S, Mittendorf EA, Yang W. Abstract P4-02-04: Quantitative MRI features analysis for differentiation of triple negative and HER2 positive subtypes of breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p4-02-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Objective: The aim of this study was to evaluate ability of quantitative analysis of MRI features to distinguish triple negative (TN) and HER2 positive (HER2+) subtypes of breast cancer, which have different biological characteristics, exhibiting different growth patterns and response to treatment.
Materials and Method: Breast cancer patients, who had MRI exam of the breast in our institution at the time of staging for breast carcinoma and who subsequently had surgery (segmentectomy or mastectomy) from January 1, 2008 through December 31, 2015 were identified. All lesions were evaluated by radiologists in accordance with the BI-RADS lexicon. The patient's age, breast cancer histology, multifocality/multicentricity (MF/MC), lesion size, axillary lymphadenopathy (LAN), MRI morphologic and enhancement characteristics were documented. Quantitative MRI feature analysis was performed using shape, texture, and histogram based features. Machine-learning-based (Xgboost) models were used to predict subtypes, and Leave-one-out cross-validation (LOOCV) was used to avoid model overfitting. Statistical significance was determined using the Student's t-test.
Results: Total of 105 patients, 51 patients with TN and 54 patients with HER2+ breast cancer were included in analysis. Mean age for TN was 50 (range 29-79)) years old and for HER2+ was 49 (range 25-70) years old. Axillary LAN and MF/MC disease was seen more commonly in HER2+ patients when compared to TN patients, but didn't reach statistical significance (13 vs 7, p=0.9; and 31 vs 20, p=0.06, respectively). Mass rim enhancement was associated with TN subtype and irregular mass enhancement was associated with HER2+ subtype of breast cancer (p<0.05). Quantitative analysis showed that six out of the top 10 ranked MRI features: surface to volume ratio, difference variance, difference entropy, inverse difference moment, 75 percentile in histogram and sum average, were significantly different between these 2 subtypes with p<0.05. When the significant features were incorporated to distinguish TN and HER+ subtypes, use of the top 2 features achieved the best accuracy on LOOCV of 0.69.
Conclusion: The quantitative MRI features show promise in distinguishing TN and HER2+ breast cancer subtypes reflecting their underlying biological characteristics and may be used as predictive quantitative biological markers. Further studies in a larger cohort evaluating associations with treatment response are underway.
FeatureIndexP-valueSurface to volume ratioShape30.005Difference VarianceGLCM110.005Difference EntropyGLCM100.009Inverse Difference MomentGLCM50.01875 percentile in histogramHistogram50.043Sum AverageGLCM60.044Median in histogramHistogram 30.08025 percentile in histogramHistogram 40.095VolumeShape10.104Max in histogramHistogram 10.105
Citation Format: Rauch GM, Li H, Zhu H, Adrada BE, Santiago L, Candelaria RP, Wang H, Leung J, Thompson A, Litton J, Wu Y, Lim B, Moulder S, Mittendorf EA, Yang W. Quantitative MRI features analysis for differentiation of triple negative and HER2 positive subtypes of breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-02-04.
Collapse
Affiliation(s)
- GM Rauch
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - H Li
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - H Zhu
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - BE Adrada
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - L Santiago
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - RP Candelaria
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - H Wang
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - J Leung
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - A Thompson
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - J Litton
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Y Wu
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - B Lim
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S Moulder
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - EA Mittendorf
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - W Yang
- The University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
20
|
Willey JS, Marx AN, Lim B, Ibrahim NK, Valero V, Mittendorf EA, Reuben JM, Le-Petross HT, Whitman GJ, Krishnamurthy S, Woodward WA, Lucci A, Liu DD, Shen Y, Ueno NT. Abstract OT1-01-05: A phase II study using talimogene laherparepvec as a single agent for inflammatory breast cancer or non-inflammatory breast cancer patients with inoperable local recurrence. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot1-01-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Objective: The primary purpose of the study is to determine the local and systemic antitumor efficacy of talimogene laherparepvec in locally recurrent breast cancer patients with or without distant metastases, as evidenced by improved overall response rates. This will be the first study to use biopsy of distant disease to demonstrate whether systemic immune modulation has antitumor efficacy in breast cancer patients.
BACKGROUND: Patients with locally recurrent breast disease frequently undergo multimodal treatment at the first occurrence of breast cancer, and because local treatment modalities such as surgical intervention and radiation are difficult to add, they subsequently receive systemic therapy. Talimogene laherparepvec (T-VEC) was developed to eliminate solid tumors and has since been considered as a potential treatment option for body surface tumors. In addition to T-VECinjected area, this agent is capable of modifying the immune response with the potential of inhibiting distant metastases. Hence, locally recurrent breast disease could benefit from T-VECregardless of concomitant distant metastases, and may offer a new local treatment option.
Study Design and Treatment Plan: This is a single agent phase II study. Patients with breast cancer who have recurrence of chest wall disease with or without distant metastasis, have at least 1 injectable lesion ≥5 mm in longest diameter or multiple injectable lesions that in aggregate have a longest diameter of ≥ 5 mm, and meet inclusion and exclusion criteria will be eligible to participate in the study. Patient will receive T-VEC via intra-tumoral injection every 2 weeks after the first initial injection (3 weeks).
STATISTICAL METHODS:
Up to 35 patients will be enrolled in the study. The trial will be conducted using a two-stage design and the overall response rate will be estimated accordingly. It is assumed that the talimogene laherparepvec single agent will have a response rate of 20%. A response rate of 5% or lower will be considered treatment failure and the regimen will be rejected under this circumstance.
Status of the study:
Activation Date: Aug 2016. 6 patients have been treated. Enrollment continues.
Sponsor: Amgen
State of Texas appropriation for rare and aggressive breast cancer research.
Citation Format: Willey JS, Marx AN, Lim B, Ibrahim NK, Valero V, Mittendorf EA, Reuben JM, Le-Petross HT, Whitman GJ, Krishnamurthy S, Woodward WA, Lucci A, Liu DD, Shen Y, Ueno NT. A phase II study using talimogene laherparepvec as a single agent for inflammatory breast cancer or non-inflammatory breast cancer patients with inoperable local recurrence [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT1-01-05.
Collapse
Affiliation(s)
- JS Willey
- MD Anderson Cancer Center, Houston, TX
| | - AN Marx
- MD Anderson Cancer Center, Houston, TX
| | - B Lim
- MD Anderson Cancer Center, Houston, TX
| | | | - V Valero
- MD Anderson Cancer Center, Houston, TX
| | | | - JM Reuben
- MD Anderson Cancer Center, Houston, TX
| | | | | | | | | | - A Lucci
- MD Anderson Cancer Center, Houston, TX
| | - DD Liu
- MD Anderson Cancer Center, Houston, TX
| | - Y Shen
- MD Anderson Cancer Center, Houston, TX
| | - NT Ueno
- MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
21
|
Rauch GM, Zhu H, Li H, Adrada BE, Santiago L, Candelaria RP, Wang H, Leung J, Litton J, Wu Y, Murthy R, Mittendorf EA, Yang W. Abstract PD2-09: Association of quantitative MRI features with tumor infiltrating lymphocytes and treatment response prediction in HER2 positive subtype of breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd2-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Objectives: To evaluate associations between qualitative and quantitative MRI features and tumor infiltrating lymphocytes (TIL) levels in HER2+ subtype of breast cancer, as potential prognostic non-invasive imaging markers for treatment response prediction.
Materials and Methods: Retrospective review of breast cancer patients who had MRI at staging, neoadjuvant chemotherapy and surgery from January 1, 2008 through December 31, 2015 was performed. BI-RADS lexicon was used for lesion evaluation. Demographic, imaging, and pathologic data including TIL levels were documented. Quantitative MRI texture analysis was performed using 3 types of textural features (TF): local binary patterns (LBP), gray-level co-occurrence matrix (GLCM), and threshold adjacency statistics (TAS). Associations between MRI quantitative TF, TIL levels, and pathologic complete response (pCR) were evaluated by Pearson correlation and logistic regression.
Results: There were 50 HER2+ patients (median age 51 years, range 29-59) with pretreatment MRI and TIL status for analysis; 27 patients had pCR at surgery. Qualitative MRI analysis showed that mass rim-enhancement (p<0. 05) and fast early enhancement kinetics (p<0.01) were associated with higher TIL levels. No association between qualitative MRI features and pCR was found. Nine TF significantly correlated with pCR (p<0.05): angular 2nd moment (GLCM), 75 percentile (LBP), standard deviation (GLCM), adjacency 0-5 (TAS). This is indicative of association of tumor heterogeneity with pCR. Three TF were significantly associated with high TIL levels (p<0.05): standard deviation, adjacency 1 and 2. Additional four TF had high association with TIL (p<0.1): sum entropy, adjacency 0, 3 and 4. These findings showed that increased heterogeneity, complexity and entropy were associated with high TIL level. Three TF were significantly associated with both, pCR and TIL (p<0.05): 75 percentile, standard deviation, adjacency 8.
Conclusion: Quantitative tumor texture analysis based on statistical modeling showed specific nine TF indicative of tumor heterogeneity associated with pCR; and seven TF indicative of increased heterogeneity, complexity, and entropy associated with high TIL levels in HER2+ breast cancer. Analysis of associations of MRI quantitative TF with pCR and TIL in HER2+ breast cancer may help to develop prognostic non-invasive imaging markers for treatment response prediction.
Citation Format: Rauch GM, Zhu H, Li H, Adrada BE, Santiago L, Candelaria RP, Wang H, Leung J, Litton J, Wu Y, Murthy R, Mittendorf EA, Yang W. Association of quantitative MRI features with tumor infiltrating lymphocytes and treatment response prediction in HER2 positive subtype of breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD2-09.
Collapse
Affiliation(s)
- GM Rauch
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - H Zhu
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - H Li
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - BE Adrada
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - L Santiago
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - RP Candelaria
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - H Wang
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - J Leung
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - J Litton
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Y Wu
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - R Murthy
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - EA Mittendorf
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - W Yang
- The University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
22
|
Reddy SM, Reuben A, Jiang H, Roszik J, Tetzlaff MT, Reuben J, Wang L, Tsujikawa T, Barua S, Rao A, Villareal L, Wood A, Woodward W, Ueno NT, Krishnamurthy S, Wargo JA, Mittendorf EA. Abstract P3-05-08: Lymphoid and myeloid cell characterization of inflammatory breast cancer tumor microenvironment and correlation to pathological complete response. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-05-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Inflammatory breast cancer (IBC) is an aggressive form of breast cancer with poor response rates to current chemotherapy regimens. With recent successes of immune targeted therapies in other solid tumors and a growing understanding of how the immune tumor microenvironment (TME) affects non-IBC outcomes, we sought to characterize the immune TME in IBC to identify biomarkers of treatment response and potential targets for drug development.
Methods: Pre-treatment core biopsy samples were identified from the MD Anderson Cancer Center IBC tissue bank from patients with stage III and de novo stage IV (with T4d) disease who received neoadjuvant chemotherapy (NAC) with intent to take to mastectomy. Lymphocytes were characterized by stromal tumor infiltrating lymphocyte (sTIL) quantification, CD8 T cell quantification, and T cell receptor sequencing. PD-L1 expression was assessed using DAKO 22C3 clone on tumor and immune cells. Myeloid cells were characterized using a multiplex immunohistochemistry approach, using CD68 and CD163 for macrophage markers, tryptase for mast cell marker, HLA-DR for class II antigen presentation marker, and cytokeratin as tumor marker. Spatial analyses were performed by determining probabilities of finding cell 1 of interest within 20 uM of cell 2 of interest and computing area under the curve for statistical comparison.
Results: 91 patients with stage III (N=62) or de novo stage IV (n=29) disease were identified. Breast cancer subtype included 25 triple negative, 34 HER2+ and 32 HER2-HR+. 86 patients received a mastectomy, of whom 33 (38.4%) patients experienced a pathologic complete response (pCR). sTIL was higher in stage III tumors (11.9 vs 4.8%, p<0.001) and in those having a pCR (13.8 vs 7.3%, p=0.019). CD8 T cell density (available in 48 cases) similarly was higher in stage III patients (360.3 vs 178.8 counts/mm2, p=0.040) and pCR cases (452.3 vs 219.2 counts/mm2, p=0.080) but also higher in HER2+ disease (560.9 for HER2+ vs 239.9 counts/mm2, p=0.087 for TNBC and 153.6 counts/mm2, p=0.005 for HER2-HR+). T cell clonality (available in 32 cases) ranged from 0.004 to 0.242 but showed no correlation to tumor characteristics or response. PD-L1 complete tumor membranous expression was seen in only 1 of 47 cases, whereas PD-L1 positivity on immune cells was seen on 36.2% of cases; neither correlated to response. Myeloid cell assessment (available in 25 cases) showed higher mast cell infiltration in non-pCR cases (63.8 vs 26.8 counts/mm2, p=0.008) and spatial analysis (performed on 10 cases) identified that closer proximity of mast cells to CD8 T cells correlates with response (AUC 6.0 vs 2.2, p=0.017), suggesting a possible immunosuppressive mechanism. HLA-DR analysis demonstrated no difference by response as a single stain marker, but co-localization of HLA-DR with cell type shows higher HLA-DR expression on tumor cells in non-responders (14.6 vs 1.6%, p=0.031).
Conclusions: Higher TIL and CD8 T cell density are correlated with improved responses to NAC in IBC. Mast cell infiltration and HLA-DR expression on tumor cells are inversely correlated to response and suggest possible mechanisms of resistance. Mast cells could present potential therapeutic target in IBC.
Citation Format: Reddy SM, Reuben A, Jiang H, Roszik J, Tetzlaff MT, Reuben J, Wang L, Tsujikawa T, Barua S, Rao A, Villareal L, Wood A, Woodward W, Ueno NT, Krishnamurthy S, Wargo JA, Mittendorf EA. Lymphoid and myeloid cell characterization of inflammatory breast cancer tumor microenvironment and correlation to pathological complete response [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-05-08.
Collapse
Affiliation(s)
- SM Reddy
- The University of Texas MD Anderson Cancer Center, Houston, TX; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX; Oregon Health and Sciences University, Portland, OR; Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - A Reuben
- The University of Texas MD Anderson Cancer Center, Houston, TX; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX; Oregon Health and Sciences University, Portland, OR; Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - H Jiang
- The University of Texas MD Anderson Cancer Center, Houston, TX; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX; Oregon Health and Sciences University, Portland, OR; Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - J Roszik
- The University of Texas MD Anderson Cancer Center, Houston, TX; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX; Oregon Health and Sciences University, Portland, OR; Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - MT Tetzlaff
- The University of Texas MD Anderson Cancer Center, Houston, TX; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX; Oregon Health and Sciences University, Portland, OR; Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - J Reuben
- The University of Texas MD Anderson Cancer Center, Houston, TX; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX; Oregon Health and Sciences University, Portland, OR; Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - L Wang
- The University of Texas MD Anderson Cancer Center, Houston, TX; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX; Oregon Health and Sciences University, Portland, OR; Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - T Tsujikawa
- The University of Texas MD Anderson Cancer Center, Houston, TX; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX; Oregon Health and Sciences University, Portland, OR; Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - S Barua
- The University of Texas MD Anderson Cancer Center, Houston, TX; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX; Oregon Health and Sciences University, Portland, OR; Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - A Rao
- The University of Texas MD Anderson Cancer Center, Houston, TX; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX; Oregon Health and Sciences University, Portland, OR; Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - L Villareal
- The University of Texas MD Anderson Cancer Center, Houston, TX; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX; Oregon Health and Sciences University, Portland, OR; Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - A Wood
- The University of Texas MD Anderson Cancer Center, Houston, TX; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX; Oregon Health and Sciences University, Portland, OR; Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - W Woodward
- The University of Texas MD Anderson Cancer Center, Houston, TX; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX; Oregon Health and Sciences University, Portland, OR; Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - NT Ueno
- The University of Texas MD Anderson Cancer Center, Houston, TX; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX; Oregon Health and Sciences University, Portland, OR; Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - S Krishnamurthy
- The University of Texas MD Anderson Cancer Center, Houston, TX; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX; Oregon Health and Sciences University, Portland, OR; Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - JA Wargo
- The University of Texas MD Anderson Cancer Center, Houston, TX; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX; Oregon Health and Sciences University, Portland, OR; Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - EA Mittendorf
- The University of Texas MD Anderson Cancer Center, Houston, TX; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX; Oregon Health and Sciences University, Portland, OR; Kyoto Prefectural University of Medicine, Kyoto, Japan
| |
Collapse
|
23
|
Hortobagyi G, Weaver DL, Solin L, Connolly J, Mittendorf E, Winchester DJ, Rugo H, Edge SB, Giuliano A. Abstract P3-08-04: Withdrawn. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-08-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- G Hortobagyi
- The University of Texas MD Anderson Cancer Center, Houston, TX; University of Vermont, Burlington, VT; Albert Einstein Medical Center, Philadelphia, PA; Beth Israel Deaconess Medical Center, Boston, MA; NorthShore University Health System, Evanston, IL; University of California, San Francisco, San Francisco, CA; Roswell Park Cancer Institute, Buffalo, NY; Cedars Sinai Medical Center, Los Angeles, CA
| | - DL Weaver
- The University of Texas MD Anderson Cancer Center, Houston, TX; University of Vermont, Burlington, VT; Albert Einstein Medical Center, Philadelphia, PA; Beth Israel Deaconess Medical Center, Boston, MA; NorthShore University Health System, Evanston, IL; University of California, San Francisco, San Francisco, CA; Roswell Park Cancer Institute, Buffalo, NY; Cedars Sinai Medical Center, Los Angeles, CA
| | - L Solin
- The University of Texas MD Anderson Cancer Center, Houston, TX; University of Vermont, Burlington, VT; Albert Einstein Medical Center, Philadelphia, PA; Beth Israel Deaconess Medical Center, Boston, MA; NorthShore University Health System, Evanston, IL; University of California, San Francisco, San Francisco, CA; Roswell Park Cancer Institute, Buffalo, NY; Cedars Sinai Medical Center, Los Angeles, CA
| | - J Connolly
- The University of Texas MD Anderson Cancer Center, Houston, TX; University of Vermont, Burlington, VT; Albert Einstein Medical Center, Philadelphia, PA; Beth Israel Deaconess Medical Center, Boston, MA; NorthShore University Health System, Evanston, IL; University of California, San Francisco, San Francisco, CA; Roswell Park Cancer Institute, Buffalo, NY; Cedars Sinai Medical Center, Los Angeles, CA
| | - E Mittendorf
- The University of Texas MD Anderson Cancer Center, Houston, TX; University of Vermont, Burlington, VT; Albert Einstein Medical Center, Philadelphia, PA; Beth Israel Deaconess Medical Center, Boston, MA; NorthShore University Health System, Evanston, IL; University of California, San Francisco, San Francisco, CA; Roswell Park Cancer Institute, Buffalo, NY; Cedars Sinai Medical Center, Los Angeles, CA
| | - DJ Winchester
- The University of Texas MD Anderson Cancer Center, Houston, TX; University of Vermont, Burlington, VT; Albert Einstein Medical Center, Philadelphia, PA; Beth Israel Deaconess Medical Center, Boston, MA; NorthShore University Health System, Evanston, IL; University of California, San Francisco, San Francisco, CA; Roswell Park Cancer Institute, Buffalo, NY; Cedars Sinai Medical Center, Los Angeles, CA
| | - H Rugo
- The University of Texas MD Anderson Cancer Center, Houston, TX; University of Vermont, Burlington, VT; Albert Einstein Medical Center, Philadelphia, PA; Beth Israel Deaconess Medical Center, Boston, MA; NorthShore University Health System, Evanston, IL; University of California, San Francisco, San Francisco, CA; Roswell Park Cancer Institute, Buffalo, NY; Cedars Sinai Medical Center, Los Angeles, CA
| | - SB Edge
- The University of Texas MD Anderson Cancer Center, Houston, TX; University of Vermont, Burlington, VT; Albert Einstein Medical Center, Philadelphia, PA; Beth Israel Deaconess Medical Center, Boston, MA; NorthShore University Health System, Evanston, IL; University of California, San Francisco, San Francisco, CA; Roswell Park Cancer Institute, Buffalo, NY; Cedars Sinai Medical Center, Los Angeles, CA
| | - A Giuliano
- The University of Texas MD Anderson Cancer Center, Houston, TX; University of Vermont, Burlington, VT; Albert Einstein Medical Center, Philadelphia, PA; Beth Israel Deaconess Medical Center, Boston, MA; NorthShore University Health System, Evanston, IL; University of California, San Francisco, San Francisco, CA; Roswell Park Cancer Institute, Buffalo, NY; Cedars Sinai Medical Center, Los Angeles, CA
| |
Collapse
|
24
|
Yam C, Santiago L, Candelaria RP, Adrada BE, Rauch GM, Hess KR, Litton JK, Piwnica-Worms H, Mittendorf EA, Ueno NT, Lim B, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, Gilcrease MZ, Symmans WF, Moulder SL, Yang W. Abstract P6-03-05: Risk of needle-track seeding with serial ultrasound guided biopsies in triple negative breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-03-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Image-guided percutaneous needle biopsy of the breast is a common procedure. In breast cancer patients (pts) undergoing core biopsies and surgical resection on the same day, the rate of tumor cell displacement along the needle track has been reported to be up to 50%. However, the clinical significance of this finding in triple negative breast cancer (TNBC) patients (pts) undergoing serial biopsies while receiving neoadjuvant chemotherapy (NACT) is unknown. Here we report the incidence of needle-track seeding (NTS) in a cohort of TNBC pts enrolled on a molecular triaging protocol involving serial biopsies of the index breast lesion.
Methods: We reviewed the clinical records of 144 consecutive TNBC pts enrolled on a molecular triaging protocol at MD Anderson Cancer Center. Per protocol, all pts underwent a pre-treatment research biopsy and were initiated on anthracycline based NACT (AC). Pts with inadequate response to front-line NACT were encouraged to undergo additional biopsies of the index breast lesion prior to switching therapies. Serial breast ultrasound (US) was performed to monitor therapeutic response and incidental evidence of needle-track seeding noted on US was documented.
Results: Clinicopathological characteristics of the pts are summarized in Table 1. 89% (128/144) of pts had a diagnostic breast biopsy done at another center prior to presenting at MDACC. To date, we have performed 209 US guided biopsies of index breast lesions in 144 pts. 92% (193/209) of these biopsies were done mainly for research purposes. 1.4% (2/144) of pts were found to have evidence of NTS on follow up US. The first pt had a T1N0 (1.9cm), grade 3, invasive ductal carcinoma (IDC) at diagnosis. She underwent a diagnostic biopsy followed by a research biopsy before initiating AC. She was found to have NTS as well as progression of disease (PD) on follow up US after 2 cycles of AC. The second pt had a T2N0 (3cm), grade 3 IDC at diagnosis. She underwent a diagnostic biopsy at another center, followed by a research biopsy before initiating AC. Like the first pt, she was found to have NTS and PD on follow up US after 2 cycles of AC. Both pts are currently on neoadjuvant clinical trials of novel agents.
Conclusion: The rate of NTS detected on US in TNBC pts undergoing serial biopsies of index breast lesions while receiving NACT is low and further studies are needed to determine the impact of serial biopsies on long term outcomes in TNBC.
Table 1: Patient CharacteristicsCharacteristicN=144Age - Median (years, interquartile range)55 (46-62)Tumor Size Mean (cm, standard deviation)3.4 (2.2)T1 – n(%)35 (24)T2 – n(%)89 (62)T3 – n(%)19 (13)T4 – n(%)1 (1)Clinical Nodal Status Negative – n(%)74 (51)Positive – n(%)70 (49)Grade 1 – n(%)1 (1)2 – n(%)17 (12)3 – n(%)124 (86)Unknown – n(%)2 (1)Histologic Subtype Invasive ductal carcinoma – n(%)121 (84)Invasive lobular carcinoma – n(%)2 (1)Mixed ductal and lobular carcinoma – n(%)3 (2)Metaplastic carcinoma – n(%)13 (9)Not specified – n(%)5 (3)Laterality Right – n(%)72 (50)Left – n(%)72 (50)
Citation Format: Yam C, Santiago L, Candelaria RP, Adrada BE, Rauch GM, Hess KR, Litton JK, Piwnica-Worms H, Mittendorf EA, Ueno NT, Lim B, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, Gilcrease MZ, Symmans WF, Moulder SL, Yang W. Risk of needle-track seeding with serial ultrasound guided biopsies in triple negative breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-03-05.
Collapse
Affiliation(s)
- C Yam
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - L Santiago
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - RP Candelaria
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - BE Adrada
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - GM Rauch
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - KR Hess
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - JK Litton
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - H Piwnica-Worms
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - EA Mittendorf
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - NT Ueno
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - B Lim
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - RK Murthy
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S Damodaran
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - T Helgason
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - L Huo
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - AM Thompson
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - MZ Gilcrease
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - WF Symmans
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - SL Moulder
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - W Yang
- The University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
25
|
Yam C, Huo L, Hess KR, Litton JK, Yang W, Piwnica-Worms H, Mittendorf EA, Ueno NT, Lim B, Murthy RK, Damodaran S, Helgason T, Thompson AM, Santiago L, Candelaria RP, Rauch GM, Adrada BE, Symmans WF, Gilcrease MZ, Moulder SL. Abstract P1-07-22: Androgen receptor positivity is associated with nodal disease in triple negative breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p1-07-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Gene expression profiling (GEP) has identified several molecularly distinct subtypes of triple negative breast cancer (TNBC). Currently, GEP-based molecular diagnostics are not routinely used in clinical decision making due to the lack of proven benefit, costs involved and long turnaround time. However, two molecularly distinct subtypes of TNBC, the luminal androgen receptor (AR) and mesenchymal subtypes, have surrogate CLIA-certified immunohistochemical (IHC) markers, AR and vimentin (VM), respectively, which have the potential for application in the clinic. Here we report the rates of AR and VM positivity and their association with clinicopathological characteristics in a cohort of TNBC pts receiving NACT.
Methods: As part of an ongoing molecular triaging protocol, 144 pts with stage I-III TNBC underwent a pretreatment biopsy for molecular characterization (MC) prior to initiating neoadjuvant chemotherapy (NACT). IHC for AR and VM were performed using commercially available antibodies. AR+ and VM+ were defined as ≥10% and ≥50% staining, respectively. Pts were randomized 2:1 to know (intervention arm, n=93) and not know (control arm, n=51) the MC results. The charts of pts randomized to the intervention arm were reviewed. Categorical variables were analyzed using Fisher's exact test. Ordinal and continuous variables were analyzed using the Wilcoxon rank-sum test and Student's t test as appropriate.
Results: 31% (29/93) and 16% (15/93) of pts were AR+ and VM+, respectively. Only 4% (4/93) of pts were both AR+ and VM+. Clinicopathological characteristics are summarized in Table 1. AR+ pts were more likely to have clinically node positive disease as compared to AR- pts (66% vs 34%, p=0.007). There were no significant differences in clinical tumor size or grade between AR+ and AR- pts. VM+ and VM- pts had similar clinicopathological characteristics.
Conclusion: Pts with AR+ TNBC were more likely to have node positive disease. The impact of AR+ on long term outcomes should be investigated in prospective studies.
Table 1: Association between patient characteristics and AR/VM status AR VM AR+ (n=29)AR- (n=64)p-valueVM+ (n=15)VM- (n=78)p-valueAge - Median (years, interquartile range)58 (48-65)52 (46-61)0.05855 (48-64)56 (47-62)0.88Clinical Tumor Size Mean (cm, standard deviation)3.5 (1.8)3.0 (1.8)0.2872.7 (1.7)3.3 (1.9)0.31T1 – n(%)5 (17)21 (33)0.2307 (47)19 (24)0.098T2 – n(%)21 (72)36 (56) 7 (47)50 (64) T3 – n(%)3 (10)7 (11) 1 (7)9 (12) Clinical Nodal Status Negative – n(%)10 (34)42 (66)0.0078 (53)44 (56)1.00Positive – n(%)19 (66)22 (34) 7 (47)34 (44) Grade 2 – n(%)6 (21)5 (8)0.0763 (20)8 (10)0.293 – n(%)23 (79)59 (92) 12 (80)70 (90)
Citation Format: Yam C, Huo L, Hess KR, Litton JK, Yang W, Piwnica-Worms H, Mittendorf EA, Ueno NT, Lim B, Murthy RK, Damodaran S, Helgason T, Thompson AM, Santiago L, Candelaria RP, Rauch GM, Adrada BE, Symmans WF, Gilcrease MZ, Moulder SL. Androgen receptor positivity is associated with nodal disease in triple negative breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-07-22.
Collapse
Affiliation(s)
- C Yam
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - L Huo
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - KR Hess
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - JK Litton
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - W Yang
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - H Piwnica-Worms
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - EA Mittendorf
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - NT Ueno
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - B Lim
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - RK Murthy
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S Damodaran
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - T Helgason
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - AM Thompson
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - L Santiago
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - RP Candelaria
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - GM Rauch
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - BE Adrada
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - WF Symmans
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - MZ Gilcrease
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - SL Moulder
- The University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
26
|
Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson A, Helgason T, Mills GB, Piwnica-Worms H, Arun BK. A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer 2017; 3:49. [PMID: 29238749 PMCID: PMC5719044 DOI: 10.1038/s41523-017-0052-4] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2017] [Revised: 11/03/2017] [Accepted: 11/20/2017] [Indexed: 02/07/2023] Open
Abstract
This study was undertaken to determine the feasibility of enrolling breast cancer patients on a single-agent-targeted therapy trial before neoadjuvant chemotherapy. Specifically, we evaluated talazoparib in patients harboring a deleterious BRCA mutation (BRCA+). Patients with a germline BRCA mutation and ≥1 cm, HER2-negative primary tumors were eligible. Study participants underwent a pretreatment biopsy, 2 months of talazoparib, off-study core biopsy, anthracycline, and taxane-based chemotherapy ± carboplatin, followed by surgery. Volumetric changes in tumor size were determined by ultrasound at 1 and 2 months of therapy. Success was defined as 20 patients accrued within 2 years and <33% experienced a grade 4 toxicity. The study was stopped early after 13 patients (BRCA1 + n = 10; BRCA2 + n = 3) were accrued within 8 months with no grade 4 toxicities and only one patient requiring dose reduction due to grade 3 neutropenia. The median age was 40 years (range 25–55) and clinical stage included I (n = 2), II (n = 9), and III (n = 2). Most tumors (n = 9) were hormone receptor-negative, and one of these was metaplastic. Decreases in tumor volume occurred in all patients following 2 months of talazoparib; the median was 88% (range 30–98%). Common toxicities were neutropenia, anemia, thrombocytopenia, nausea, dizziness, and fatigue. Single-agent-targeted therapy trials are feasible in BRCA+ patients. Given the rapid rate of accrual, profound response and favorable toxicity profile, the feasibility study was modified into a phase II study to determine pathologic complete response rates after 4–6 months of single-agent talazoparib. An investigational PARP inhibitor seems safe and possibly effective when given ahead of surgery to women with BRCA-mutated breast cancer. Jennifer Litton and colleagues from the University of Texas MD Anderson Cancer Center in Houston, USA, conducted a small feasibility study to see if patients with stage I-III breast cancer and inherited mutations in BRCA1 or BRCA2 would put off their standard course of chemotherapy ahead of surgery to first receive two months of talazoparib, an experimental inhibitor of poly ADP ribose polymerase (PARP), an enzyme involved in DNA damage repair. The trial was a resounding success. In fact, owing to rapid patient enrollment, decreases in tumor volume among all 13 participants and few signs of serious side effects, the researchers amended the study protocol to give talazoparib for longer and test for therapeutic efficacy.
Collapse
Affiliation(s)
- J K Litton
- Department of Breast Medical Oncology, Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 USA
| | - M Scoggins
- Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 USA
| | - D L Ramirez
- Department of Breast Medical Oncology, Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 USA
| | - R K Murthy
- Department of Breast Medical Oncology, Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 USA
| | - G J Whitman
- Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 USA
| | - K R Hess
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 USA
| | - B E Adrada
- Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 USA
| | - S L Moulder
- Department of Breast Medical Oncology, Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 USA
| | - C H Barcenas
- Department of Breast Medical Oncology, Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 USA
| | - V Valero
- Department of Breast Medical Oncology, Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 USA
| | - J Schwartz Gomez
- Department of Breast Medical Oncology, Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 USA
| | - E A Mittendorf
- Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 USA
| | - A Thompson
- Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 USA
| | - T Helgason
- Department of Breast Medical Oncology, Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 USA
| | - G B Mills
- Department of Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 USA
| | - H Piwnica-Worms
- Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 USA
| | - B K Arun
- Department of Breast Medical Oncology, Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 USA
| |
Collapse
|
27
|
Jackson DO, Qiao N, Peace KM, Hale DF, Vreeland TJ, Greene JM, Berry JS, Trappey AF, Clifton GT, Ibrahim N, Toms A, Peoples GE, Mittendorf EA. Abstract P6-10-04: Determining the optimal vaccination strategy using a combination of the folate binding protein (FBP) peptide vaccine (E39+GM-CSF) and an attenuated version (E39') to maximize the immunologic response in breast cancer patients. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-10-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND FBP is overexpressed in 20-50% of breast(B) cancers(Ca) and roughly 90% of endometrial(E) and ovarian (Ov) Ca. E39 (FBP191-199, EIWTHSYKV)+GM-CSF is an HLA-A2 restricted FBP peptide vaccine, which has been shown to generate significant in vivo immunologic response(IR) in a phase I/IIa trial in E Ca and Ov Ca patients (pts). There is a risk of inducing immunologic tolerance after multiple inoculations with a highly immunogenic vaccine. Thus, we are investigating a novel vaccination series using combinations of E39 and E39' (EIWTFSTKV, an attenuated version of E39) in a phase Ib, randomized, single-center trial. We are assessing short and long-term IR. Here, we present the initial IR analysis to the primary vaccination series (PVS) within B Ca pts.
METHODS HLA-A2 positive B or Ov Ca pts were enrolled after completion of standard of care therapy and randomized into three arms: EE (6 inoculations of E39); EE'(3 inoculations of E39, then 3 of E39'); or E'E(3 of E39', then 3 of E39). Theoretically, due to lower FBP expression and less aggressive chemotherapy regimens, B Ca pts are more antigen naïve and have a less suppressed immune system. Thus, only B Ca pts were included in this analysis. The PVS includes 6 inoculations total (R1-R6), one every 3-4 weeks, and containing 250mcg GM-CSF+500mcg peptide in the first 5 pts per arm and 1000mcg of peptide in second 5 pts. To assess the in vivo IR, local reaction(LR) was measured 48 hours after each inoculation (R1-R6), and delayed type hypersensitivity(DTH) was measured pre-PVS (R0), 1, and 6-months post-PVS (RC1, RC6). Ex vivo IR was measured via dextramer assay for E39-specific CD8+ T-cells at R0, RC1, and RC6. Statistical analyses were completed using appropriate tests.
RESULTS Thirty-five B Ca pts were enrolled, with 27 completing the PVS (EE n=10, EE' n=8, E'E n=9). No clinicopathologic differences between groups or significant toxicities > grade 2 were appreciated. LR increased from R1 to R6 in all groups (ΔEE= 24.80mm, p=0.14; ΔEE'=38.13mm, p=0.07; ΔE'E=8.05mm, p=0.38), the greatest increase approaching statistical significance in the EE' arm. The only arm with a statistically significant increase for in vivo DTH from R0-RC1-RC6 was in the EE' arm (ΔEE=-6.17mm, p=0.27; ΔEE'= 44.58mm, p<0.05; ΔE'E=-1.42, p=0.37). Ex vivo analysis of IR revealed no significant difference between groups at R0(p=0.45) or RC6(p=0.72), nor within groups over time (EE p=0.32, EE' p=0.47, E'E p=0.30).
CONCLUSION In this phase Ib trial analyzing the IR of B Ca pts receiving a different vaccination strategy, both peptides were noted to be safe and immunogenic. While no difference was seen in E39-specific CD8+ T cells between groups, the in vivo response was enhanced with the use of E39' after E39; this may indicate expansion of more effective clonal populations of CD8+ T cells with this strategy. These results may be specific to B Ca pts who are relatively antigen-naïve with relatively intact immune systems. Further analysis of these pts as this trial continues will determine the optimal vaccination strategy capable of stimulating and maintaining an IR to prevent B Ca recurrence.
Citation Format: Jackson DO, Qiao N, Peace KM, Hale DF, Vreeland TJ, Greene JM, Berry JS, Trappey AF, Clifton GT, Ibrahim N, Toms A, Peoples GE, Mittendorf EA. Determining the optimal vaccination strategy using a combination of the folate binding protein (FBP) peptide vaccine (E39+GM-CSF) and an attenuated version (E39') to maximize the immunologic response in breast cancer patients [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-10-04.
Collapse
Affiliation(s)
- DO Jackson
- San Antonio Militay Medical Center, San Antonio, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Womack Army Medical Center, Fayetteville, NC; Cancer Vaccine Development Program, San Antonio, TX
| | - N Qiao
- San Antonio Militay Medical Center, San Antonio, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Womack Army Medical Center, Fayetteville, NC; Cancer Vaccine Development Program, San Antonio, TX
| | - KM Peace
- San Antonio Militay Medical Center, San Antonio, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Womack Army Medical Center, Fayetteville, NC; Cancer Vaccine Development Program, San Antonio, TX
| | - DF Hale
- San Antonio Militay Medical Center, San Antonio, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Womack Army Medical Center, Fayetteville, NC; Cancer Vaccine Development Program, San Antonio, TX
| | - TJ Vreeland
- San Antonio Militay Medical Center, San Antonio, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Womack Army Medical Center, Fayetteville, NC; Cancer Vaccine Development Program, San Antonio, TX
| | - JM Greene
- San Antonio Militay Medical Center, San Antonio, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Womack Army Medical Center, Fayetteville, NC; Cancer Vaccine Development Program, San Antonio, TX
| | - JS Berry
- San Antonio Militay Medical Center, San Antonio, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Womack Army Medical Center, Fayetteville, NC; Cancer Vaccine Development Program, San Antonio, TX
| | - AF Trappey
- San Antonio Militay Medical Center, San Antonio, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Womack Army Medical Center, Fayetteville, NC; Cancer Vaccine Development Program, San Antonio, TX
| | - GT Clifton
- San Antonio Militay Medical Center, San Antonio, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Womack Army Medical Center, Fayetteville, NC; Cancer Vaccine Development Program, San Antonio, TX
| | - N Ibrahim
- San Antonio Militay Medical Center, San Antonio, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Womack Army Medical Center, Fayetteville, NC; Cancer Vaccine Development Program, San Antonio, TX
| | - A Toms
- San Antonio Militay Medical Center, San Antonio, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Womack Army Medical Center, Fayetteville, NC; Cancer Vaccine Development Program, San Antonio, TX
| | - GE Peoples
- San Antonio Militay Medical Center, San Antonio, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Womack Army Medical Center, Fayetteville, NC; Cancer Vaccine Development Program, San Antonio, TX
| | - EA Mittendorf
- San Antonio Militay Medical Center, San Antonio, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Womack Army Medical Center, Fayetteville, NC; Cancer Vaccine Development Program, San Antonio, TX
| |
Collapse
|
28
|
Hortobagyi GN, Giuliano A, Winchester DJ, Mittendorf E, Edge S, Connolly J, Weaver D, Rugo H, Solin L. Abstract P6-09-06: Updating the AJCC TNM staging system a summary of changes. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-09-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- GN Hortobagyi
- The University of Texas MD Anderson Cancer Center, Houston, TX; Cedars Sinai Medical Center, Los Angeles, CA; NorthShore University Health System, Evanston, IL; UT MD Anderson Cancer Center, Houston, TX; Roswell Park Cancer Institute, Buffalo, NY; Beth Israel Deaconess Medical Center, Boston, MA; University of Vermont, Burlington, VT; University of California, San Francisco, San Francisco, CA; Albert Einstein Medical Center, Philadelphia, PA
| | - A Giuliano
- The University of Texas MD Anderson Cancer Center, Houston, TX; Cedars Sinai Medical Center, Los Angeles, CA; NorthShore University Health System, Evanston, IL; UT MD Anderson Cancer Center, Houston, TX; Roswell Park Cancer Institute, Buffalo, NY; Beth Israel Deaconess Medical Center, Boston, MA; University of Vermont, Burlington, VT; University of California, San Francisco, San Francisco, CA; Albert Einstein Medical Center, Philadelphia, PA
| | - DJ Winchester
- The University of Texas MD Anderson Cancer Center, Houston, TX; Cedars Sinai Medical Center, Los Angeles, CA; NorthShore University Health System, Evanston, IL; UT MD Anderson Cancer Center, Houston, TX; Roswell Park Cancer Institute, Buffalo, NY; Beth Israel Deaconess Medical Center, Boston, MA; University of Vermont, Burlington, VT; University of California, San Francisco, San Francisco, CA; Albert Einstein Medical Center, Philadelphia, PA
| | - E Mittendorf
- The University of Texas MD Anderson Cancer Center, Houston, TX; Cedars Sinai Medical Center, Los Angeles, CA; NorthShore University Health System, Evanston, IL; UT MD Anderson Cancer Center, Houston, TX; Roswell Park Cancer Institute, Buffalo, NY; Beth Israel Deaconess Medical Center, Boston, MA; University of Vermont, Burlington, VT; University of California, San Francisco, San Francisco, CA; Albert Einstein Medical Center, Philadelphia, PA
| | - S Edge
- The University of Texas MD Anderson Cancer Center, Houston, TX; Cedars Sinai Medical Center, Los Angeles, CA; NorthShore University Health System, Evanston, IL; UT MD Anderson Cancer Center, Houston, TX; Roswell Park Cancer Institute, Buffalo, NY; Beth Israel Deaconess Medical Center, Boston, MA; University of Vermont, Burlington, VT; University of California, San Francisco, San Francisco, CA; Albert Einstein Medical Center, Philadelphia, PA
| | - J Connolly
- The University of Texas MD Anderson Cancer Center, Houston, TX; Cedars Sinai Medical Center, Los Angeles, CA; NorthShore University Health System, Evanston, IL; UT MD Anderson Cancer Center, Houston, TX; Roswell Park Cancer Institute, Buffalo, NY; Beth Israel Deaconess Medical Center, Boston, MA; University of Vermont, Burlington, VT; University of California, San Francisco, San Francisco, CA; Albert Einstein Medical Center, Philadelphia, PA
| | - D Weaver
- The University of Texas MD Anderson Cancer Center, Houston, TX; Cedars Sinai Medical Center, Los Angeles, CA; NorthShore University Health System, Evanston, IL; UT MD Anderson Cancer Center, Houston, TX; Roswell Park Cancer Institute, Buffalo, NY; Beth Israel Deaconess Medical Center, Boston, MA; University of Vermont, Burlington, VT; University of California, San Francisco, San Francisco, CA; Albert Einstein Medical Center, Philadelphia, PA
| | - H Rugo
- The University of Texas MD Anderson Cancer Center, Houston, TX; Cedars Sinai Medical Center, Los Angeles, CA; NorthShore University Health System, Evanston, IL; UT MD Anderson Cancer Center, Houston, TX; Roswell Park Cancer Institute, Buffalo, NY; Beth Israel Deaconess Medical Center, Boston, MA; University of Vermont, Burlington, VT; University of California, San Francisco, San Francisco, CA; Albert Einstein Medical Center, Philadelphia, PA
| | - L Solin
- The University of Texas MD Anderson Cancer Center, Houston, TX; Cedars Sinai Medical Center, Los Angeles, CA; NorthShore University Health System, Evanston, IL; UT MD Anderson Cancer Center, Houston, TX; Roswell Park Cancer Institute, Buffalo, NY; Beth Israel Deaconess Medical Center, Boston, MA; University of Vermont, Burlington, VT; University of California, San Francisco, San Francisco, CA; Albert Einstein Medical Center, Philadelphia, PA
| |
Collapse
|
29
|
Mittendorf EA, Plitas G, Garber J, Crew K, Heckman-Stoddard B, Wojtowicz M, Vornik L, Peoples GE, Brown PH. Abstract OT3-01-04: VADIS trial: Phase II trial of the nelipepimut-S peptide v
accine in women with DC IS of the breast. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot3-01-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Our group has been investigating vaccination strategies in breast cancer. Specifically, we have been evaluating HER2-derived peptide vaccines including nelipepimut-S+GM-CSF administered adjuvantly to breast cancer patients who have been rendered disease-free with standard of care therapy but are at high risk for recurrence. Early phase clinical trials showed an approximately 50% reduction in relative recurrence risk in vaccinated patients. Based on these data, nelipepimut-S+GM-CSF is being evaluated in a phase III registration trial. Having shown the vaccine to be safe, effective in stimulating an antigen-specific immune response and potentially having clinical efficacy in the setting of secondary prevention, the current study was initiated to evaluate vaccination in DCIS patients. This trial represents an initial step to move the vaccine into the primary prevention setting.
Trial Design: Phase II, randomized, single-blind study. Patients will be randomized 2:1 to receive vaccine or GM-CSF alone. After enrollment, patients will receive 3 inoculations administered every other week preoperatively followed by surgery then completion of the vaccination series (3 additional inoculations) in the adjuvant setting.
Eligibility: The trial will enroll pre- or post-menopausal women with a diagnosis of DCIS made by core biopsy. The area of radiographic abnormality must measure at least 1 cm. Because the vaccine is a MHC class I, CD8+ T cell-eliciting vaccine, it is HLA restricted, and patients must be HLA-A2+ to enroll. Participants must also have an ECOG performance status <2, adequate cardiac, kidney and liver function and be willing to comply with all study interventions and follow-up procedures.
Specific Aims: The trial's primary endpoint is to evaluate for nelipepimut-specific CD8+ T cells in the peripheral blood of vaccinated patients compared to patients receiving GM-CSF alone. Secondary endpoints include evaluating toxicity; determining the immune response in vivo by DTH, in vitro by evaluating for epitope spreading to other tumor antigens, and importantly in the tumor by assessing the degree of lymphocytic infiltration in surgically resected specimens. The extent of HER2 expression, Ki67 and cleaved caspase 3 in the resected specimen will also be assessed.
Statistical Methods: A total of 108 DCIS patients will be consented and screened for eligibility. 48 (45%) are expected to be HLA-A2 positive. These 48 patienst will be randomized 2:1 to vaccine or GM-CSF alone groups. Accounting for 10% attrition rate and for an approximately 5% non-evaluable sample rate, we expect to have 40 evaluable patients, 27 in the vaccine group and 13 in the GM-CSF alone group, that have baseline, pre-surgery, and post-surgery measures of nelipepimut-S-specific CD8+ T cells. We will have 82% power to detect a significant increase in nelipepimut-S-specific CD8+ T cells in the vaccine group versus the GM-CSF alone group.
Contact Info: The study is accruing at four sites to include Columbia University, Dana Farber Cancer Institute, MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center. Additional information can be obtained from the overall study PI, Dr. Elizabeth Mittendorf (eamitten@mdanderson.org). NCT0236582.
Citation Format: Mittendorf EA, Plitas G, Garber J, Crew K, Heckman-Stoddard B, Wojtowicz M, Vornik L, Peoples GE, Brown PH. VADIS trial: Phase II trial of the nelipepimut-S peptide vaccine in women with DCIS of the breast [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT3-01-04.
Collapse
Affiliation(s)
- EA Mittendorf
- The University of Texas MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Dana Farber Cancer Insitute; Columbia University; National Cancer Institute; Cancer Insight
| | - G Plitas
- The University of Texas MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Dana Farber Cancer Insitute; Columbia University; National Cancer Institute; Cancer Insight
| | - J Garber
- The University of Texas MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Dana Farber Cancer Insitute; Columbia University; National Cancer Institute; Cancer Insight
| | - K Crew
- The University of Texas MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Dana Farber Cancer Insitute; Columbia University; National Cancer Institute; Cancer Insight
| | - B Heckman-Stoddard
- The University of Texas MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Dana Farber Cancer Insitute; Columbia University; National Cancer Institute; Cancer Insight
| | - M Wojtowicz
- The University of Texas MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Dana Farber Cancer Insitute; Columbia University; National Cancer Institute; Cancer Insight
| | - L Vornik
- The University of Texas MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Dana Farber Cancer Insitute; Columbia University; National Cancer Institute; Cancer Insight
| | - GE Peoples
- The University of Texas MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Dana Farber Cancer Insitute; Columbia University; National Cancer Institute; Cancer Insight
| | - PH Brown
- The University of Texas MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Dana Farber Cancer Insitute; Columbia University; National Cancer Institute; Cancer Insight
| |
Collapse
|
30
|
Chavez-MacGregor M, Mittendorf EA, Clarke CA, Lichensztajn DY, Hunt KK, Giordano SH. Abstract P5-08-02: Improving the AJCC breast cancer staging system by incorporating tumor biomarkers. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-08-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: The current American Joint Committee on Cancer (AJCC) breast cancer staging system provides important prognostic information, however its use is limited by the lack of data incorporating prognostic and predictive biological markers. In this study we sought to determine the relationship between stage, breast cancer subtype, grade and outcome in a large population-based cohort, and to develop a risk score point-based system incorporating biological factors to the current AJCC staging system.
METHODS: Patients diagnosed with primary breast cancer stage I-IV, between 2005-2008 were identified in the California Cancer Registry. For patients with stage I-III disease, pathological stage was recorded. For those with stage IV, clinical stage was used. 5 year-breast cancer specific survival (BCSS) and overall survival (OS) rates were determined for each potential TNM combination according to breast cancer subtype. Cox proportional hazard models were used to identify independent predictors of outcome. A risk score point-based system (range 0-3 points) was created to complement the current anatomic AJCC staging system. One point was assigned for each one of the following tumor characteristics: hormone receptor (HR)-negative status, HER2-negative status and grade 3. Survival probabilities between groups were compared using log-rank test. Multivariable analysis models according to stage and risk score were performed for BCSS and OS.
RESULTS: A total of 43,938 patients were included. The 5-year BCSS and OS for each TNM combination differed according to breast cancer subtype. The best outcomes were seen among HR-positive patients followed closely by those with HER2-positive and HR-positive tumors with the worst outcomes observed among patients with triple negative tumors. In a multivariable model, after adjusting for stage, treatment variables and other important confounders, ER negative status (OR 2.14; 95%CI 1.98-2.30), HER2-negative status (OR= 1.24; 95%CI1.14-1.34) and grade 3 (OR=2.03; 95% CI 1.88-2.20) were independent predictors of BCSS. Our risk score system separated patients into 4 risk groups within each stage category (all P<0.05). Similar results were seen for OS. The results in the table show that combining stage and risk score provides improved prognostic information.
Hazard ratios for BCSS according to stage and risk score.Stage/Risk ScoreHazard Ratio95%CII-0Reference I-10.630.42-0.97I-22.811.87-4.23I-34.902.79-8.61IIA-03.652.26-5.91IIA-12.241.50-3.33IIA-25.873.94-8.73IIA-39.356.24-13.99IIB-04.763.13-7.24IIB-15.043.37-7.53IIB-29.465.63-15.92IIB-314.599.78-21.79IIIA-09.136.12-13.62IIIA-17.384.92-11.06IIIA-212.017.14-20.19IIIA-332.5421.59-49.04IIIB-018.9712.62-28.52IIIB-119.0512.68-28.61IIIB-228.3418.91-42.47IIIB-335.6121.33-59.43IIIC-011.525.84-22.74IIIC-115.766.07-40.94IIIC-226.7716.74-42.83IIIC-356.6336.60-87.60IV-049.9330.64-81.36IV-167.4545.36-100.23IV-2107.6272.36-60.07IV-3164.04107.18-251.04
CONCLUSIONS: Incorporating biological factors to the current AJCC staging system provides more accurate prognostic information and reflects current treatment practice. The proposed risk score improves the AJCC breast cancer staging system and should be incorporated in the upcoming revision.
Citation Format: Chavez-MacGregor M, Mittendorf EA, Clarke CA, Lichensztajn DY, Hunt KK, Giordano SH. Improving the AJCC breast cancer staging system by incorporating tumor biomarkers [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-08-02.
Collapse
Affiliation(s)
| | - EA Mittendorf
- MD Anderson Cancer Center; Cancer Prevention Institute of California
| | - CA Clarke
- MD Anderson Cancer Center; Cancer Prevention Institute of California
| | - DY Lichensztajn
- MD Anderson Cancer Center; Cancer Prevention Institute of California
| | - KK Hunt
- MD Anderson Cancer Center; Cancer Prevention Institute of California
| | - SH Giordano
- MD Anderson Cancer Center; Cancer Prevention Institute of California
| |
Collapse
|
31
|
Moulder S, Hess K, Rauch M, Astrada B, Litton J, Mittendorf E, Ueno N, Tripathy D, Lim B, Piwnica-Worms H, Thompson A, Symmans WF. Abstract OT2-01-22: NCT02456857: A phase II trial of liposomal doxorubicin, bevacizumab and everolimus (DAE) in patients (pts) with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot2-01-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Approximately 50% of TNBC pts treated with standard taxane/anthracycline-based NACT will have chemo-insensitive disease (CID) manifested as extensive residual disease (RCB-II or III) at the time of surgery. 40-80% of these pts will develop recurrence within 3 years of initial diagnosis. Recent advances in molecular profiling have identified subsets of TNBC with distinct, targetable molecular features. We developed a clinical trial to identify and characterize CID (ARTEMIS: A Randomized, TNBC Enrolling trial to confirm Molecular profiling Improves Survival). In the ARTEMIS trial, treatment naïve pts with localized TNBC undergo a pretreatment biopsy and then immediately start their initial phase of anthracycline-based chemotherapy so that the results of the molecular characterization are used in combination with response assessment (clinical exam/diagnostic imaging) to identify CID and inform the second phase of NACT, thus using a 'second hit' strategy in the middle of NACT to overcome drug resistance. The mesenchymal subtypes of TNBC have a high incidence of PI3K pathway activation. Preclinical models demonstrated response to PI3K inhibitors in this subtype. Metaplastic breast cancers make up ∼30% of tumors characterized as 'claudin-low/mesenchymal' by gene signature and are also associated with a high rate of PI3K activating molecular aberrations. A combination regimen of liposomal doxorubicin, bevacizumab and the mTOR inhibitors temsirolimus or everolimus (DAT or DAE) demonstrated response (including durable complete responses) in metastatic metaplastic breast cancer.
PRIMARY OBJECTIVE: Determine the rate of pathologic complete response (pCR/RCB-0) or minimal residual disease (RCB-I) after 4 cycles of DAE for treatment of mesenchymal TNBC deemed to be CID through the ARTEMIS trial
TRIAL DESIGN AND STATISTICAL METHODS: Only pts deemed to have mesenchymal CID on the ARTEMIS trial can enter this non-randomized phase II study. Realizing that pts without response to their initial cycles of chemotherapy have very low chance (5%) of achieving pCR with additional cycles of chemotherapy, it would be clinically meaningful to see pCR in this pt population improved to 20%. Counting pCR (RCB-0) or RCB-I as response, a two-stage Gehan-type design will be employed with 14 pts in the first stage. If at least one pt responds, 23 more pts will be added for a total of 37 pts. This design has a 49% chance of terminating after the first stage if the true response rate is 0.05, 23% chance if the true rate is 0.10, 10% if the true rate is 0.15 and 4% if the true rate is 0.20. If accrual continues to the second stage and a total of 37 pts are enrolled, the 95% confidence interval for a 0.20 response rate will extend from 0.10 to 0.35.
BRIEF ELIGIBILITY CRITERIA: Inclusion: localized TNBC enrolled onto ARTEMIS trial, adequate organ, bone marrow and cardiac parameters Exclusion: metastatic disease, pregnant or lactating pts, medical illness that increases chance of moderate to severe toxicity
CORRELATIVE SCIENCE: Correlate vimentin expression by IHC, mesenchymal signatures and PI3K pathway aberrations with response.
Citation Format: Moulder S, Hess K, Rauch M, Astrada B, Litton J, Mittendorf E, Ueno N, Tripathy D, Lim B, Piwnica-Worms H, Thompson A, Symmans WF. NCT02456857: A phase II trial of liposomal doxorubicin, bevacizumab and everolimus (DAE) in patients (pts) with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT2-01-22.
Collapse
Affiliation(s)
- S Moulder
- University of Texas, MD Anderson Cancer Center
| | - K Hess
- University of Texas, MD Anderson Cancer Center
| | - M Rauch
- University of Texas, MD Anderson Cancer Center
| | - B Astrada
- University of Texas, MD Anderson Cancer Center
| | - J Litton
- University of Texas, MD Anderson Cancer Center
| | | | - N Ueno
- University of Texas, MD Anderson Cancer Center
| | - D Tripathy
- University of Texas, MD Anderson Cancer Center
| | - B Lim
- University of Texas, MD Anderson Cancer Center
| | | | - A Thompson
- University of Texas, MD Anderson Cancer Center
| | - WF Symmans
- University of Texas, MD Anderson Cancer Center
| |
Collapse
|
32
|
Litton JK, Moulder S, Helgason T, Clayborn AR, Rauch GM, Gilcrease M, Adrada BE, Huo L, Hess KR, Symmans WF, Thompson A, Tripathy D, Mittendorf EA. Abstract OT2-01-14: Triple-negative first-line study: Neoadjuvant trial of nab-paclitaxel and atezolizumab, a PD-L1 inhibitor, in patients with triple negative breast cancer (TNBC) (NCT02530489). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot2-01-14] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: TNBC has an especially poor prognosis in patients (pts) whose tumor does not respond to anthracycline and taxane-based chemotherapy. Approximately 50% will have chemo-insensitive disease (CID) resulting in extensive residual disease at the time of surgery. 40-80% of these pts will recur < 3 years. Recently developed molecular profiling techniques to identify TNBC subsets detect distinct molecular hallmarks. We designed a clinical trial to identify and characterize CID (ARTEMIS: A Randomized, TNBC Enrolling trial to confirm Molecular profiling Improves Survival). Treatment naïve pts with localized TNBC undergo a pretreatment biopsy followed by anthracycline-based chemotherapy (AC). During AC the molecular profile is determined; these results along with the response assessment (clinical exam/diagnostic imaging) will identify CID and guide the second phase of neoadjuvant chemotherapy. Tumor-infiltrating lymphocytes (TIL) have been identified as having prognostic and predictive significance in TNBC pts leading to higher pCR rates post NACT. However, the tumor microenvironment also contains regulatory T cells and myeloid-derived suppressor cells that are immunosuppressive. Programmed death ligand 1 (PD-L1) is expressed in 20% TNBC. Targeting this may lead to a more durable response as compared to chemotherapy alone.
PRIMARY OBJECTIVE: Evaluate the rate of pathologic complete response (pCR)/RCB-0 + residual cancer burden (RCB)-I responses in TNBC pts, determined to have CID after anthracycline-based chemotherapy, then treat with atezolizumab + nab-paclitaxel preoperatively.
TRIAL DESIGN AND STATISITCAL METHODS: Pts deemed to have CID on the ARTEMIS trial can enter this non-randomized phase II study. Pts without response to their initial chemotherapy cycles have a low likelihood (5%) of achieving pCR with additional cycles of chemotherapy. It would be clinically meaningful for pCR to improve to 20%. Counting pCR (RCB-0) or RCB-I as response given similar survival outcomes, a two-stage Gehan-type design will be employed with 14 pts in the first stage. If at least one pt responds, 23 more will be added. This design has a 49% chance of terminating after the first stage if the true response rate is 0.05, 23% chance if the true rate is 0.10, 10% if the true rate is 0.15 and 4% if the true rate is 0.20. If accrual continues to the second stage, the 95% confidence interval for a 0.20 response rate will extend from 0.10 to 0.35.
BRIEF ELIGIBILITY CRITERIA: Inclusion: localized TNBC enrolled onto ARTEMIS and determined to have CID at the time of response assessment after anthracycline chemotherapy, adequate organ, bone marrow and cardiac parameters. Exclusion: prior immunotherapy, IBC, history of autoimmune disease, HIV, Hep-B, Hep-C, active tuberculosis, pregnant.
CORRELATIVE SCIENCE: Evaluate the presence and phenotype of TIL and other immune cell populations in tumor tissue pre/post treatment; determine changes in expression of co-stimulatory and co-inhibitory molecules on tumor cells and immune cells in the microenvironment; evaluate the immune repertoire and cytokine responses in serially collected peripheral blood mononuclear cells and serum respectively.
Citation Format: Litton JK, Moulder S, Helgason T, Clayborn AR, Rauch GM, Gilcrease M, Adrada BE, Huo L, Hess KR, Symmans WF, Thompson A, Tripathy D, Mittendorf EA. Triple-negative first-line study: Neoadjuvant trial of nab-paclitaxel and atezolizumab, a PD-L1 inhibitor, in patients with triple negative breast cancer (TNBC) (NCT02530489) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT2-01-14.
Collapse
Affiliation(s)
- JK Litton
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S Moulder
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - T Helgason
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - AR Clayborn
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - GM Rauch
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - M Gilcrease
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - BE Adrada
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - L Huo
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - KR Hess
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - WF Symmans
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - A Thompson
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - D Tripathy
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - EA Mittendorf
- The University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
33
|
Ross MI, Black DM, Mittendorf EA, Porretta JM, Bedrosian I, Caudle AS, Hwang RF, Meric-Bernstam F, Babiera GV, Brulotte M, Andtbacka RHI, Matsen CB. Abstract P2-01-05: A phase II clinical trial of VST-1001 (dilute fluorescein) in lymphatic mapping and sentinel lymph node localization in clinically node negative breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-01-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Combined use of a radiocolloid and a vital blue dye is recommended for accurate lymphatic mapping and sentinel lymph node (SLN) identification in breast cancer. However, vital blue dyes can cause tattooing, skin necrosis and severe allergic reactions. Moreover, the vital blue dyes are only able to detect 70% or less of SLNs in large multi-center trials. Hence, there is an unmet need to develop new lymphatic mapping agents that could potentially replace vital blue dyes. We have previously, in a Phase I trial, reported on the safety of VST-1001 (dilute fluorescein) in SLN identification. Here we report the Phase II data of VST-1001 and direct visualization devices in lymphatic mapping, SLN identification, and safety in clinically node negative breast cancer.
Methods: This prospective Phase II, multi-center, non-randomized, single-arm, open-label, single-dose clinical trial enrolled patients (pts) with DCIS and clinical stage I/II breast cancer eligible for SLN biopsy. All pts had SLN localization with technetium-99m-sulfur colloid (Tc99mSC) and intraoperative lymphatic mapping with 0.1% VST-1001 injected peritumorally, periareolarly, and/or intradermally. SLN radioactivity was identified with a gamma probe, and VST-1001 fluorescence was induced by light emitting diodes and detected as yellowish-green fluorescence in the visible light range with notch filter spectacles. The primary endpoint was the ability of VST-1001 to localize lymph nodes. SLN concordance of Tc99mSC radioactivity and VST-1001 fluorescence, and safety were also assessed.
Results: Eighty-seven women and 2 men with a median age of 60 yrs (range, 37-77) were enrolled. Primary tumor T-stage was: 12.4% T0, 62.9% T1, 23.6% T2, and 1.1% T3. Of the 89 pts, 87 (97.8%) had at least 1 radioactive SLN, and 86 (96.6%) at least 1 fluorescent SLN. Of a total of 198 SLN identified (mean 2.2 SLN/pt), 74.2% were fluorescent and radioactive, 11.6% were radioactive only, 8.6% were fluorescent only, and 5.1% were not radioactive or fluorescent. 82.8% of all SLNs were fluorescent. Twelve (13.5%) pts had microscopic metastatic breast cancer in 14 (7.1%) SLNs. Of the 14 SLNs with metastasis, 12 (85.7%) were both radioactive and fluorescent, 1 (7.1%) fluorescent only and 1 (7.1%) not radioactive or fluorescent and only suspicious on palpation. The fluorescent only SLN was identified in a patient with only 1 SLN and without VST-1001 the metastasis would have been missed. The only adverse event related to VST-1001 was intraoperative grade 2 allergic reaction of the ipsilateral breast in one pt. Intravenous anti-histamines were administered and the erythema resolved.
Conclusions: VST-1001 safely localized lymph nodes in breast cancer. VST-1001 was able to localize lymph nodes that were not radioactive and had a high co-localization concordance with Tc99mSC. VST-1001 also appears to have a higher rate of SLN localization compared to that historically reported for vital blue dyes. In light of these data, VST-1001 may be an alternative SLN localizing agent to be used in conjunction with Tc99mSC in breast cancer pts, eliminating many of adverse events observed when using vital blue dyes without compromising SLN identification.
Citation Format: Ross MI, Black DM, Mittendorf EA, Porretta JM, Bedrosian I, Caudle AS, Hwang RF, Meric-Bernstam F, Babiera GV, Brulotte M, Andtbacka RHI, Matsen CB. A phase II clinical trial of VST-1001 (dilute fluorescein) in lymphatic mapping and sentinel lymph node localization in clinically node negative breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-01-05.
Collapse
Affiliation(s)
- MI Ross
- University of Texas MD Anderson Cancer Center, Houston, TX; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Vestan Inc., Salt Lake City, UT
| | - DM Black
- University of Texas MD Anderson Cancer Center, Houston, TX; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Vestan Inc., Salt Lake City, UT
| | - EA Mittendorf
- University of Texas MD Anderson Cancer Center, Houston, TX; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Vestan Inc., Salt Lake City, UT
| | - JM Porretta
- University of Texas MD Anderson Cancer Center, Houston, TX; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Vestan Inc., Salt Lake City, UT
| | - I Bedrosian
- University of Texas MD Anderson Cancer Center, Houston, TX; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Vestan Inc., Salt Lake City, UT
| | - AS Caudle
- University of Texas MD Anderson Cancer Center, Houston, TX; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Vestan Inc., Salt Lake City, UT
| | - RF Hwang
- University of Texas MD Anderson Cancer Center, Houston, TX; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Vestan Inc., Salt Lake City, UT
| | - F Meric-Bernstam
- University of Texas MD Anderson Cancer Center, Houston, TX; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Vestan Inc., Salt Lake City, UT
| | - GV Babiera
- University of Texas MD Anderson Cancer Center, Houston, TX; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Vestan Inc., Salt Lake City, UT
| | - M Brulotte
- University of Texas MD Anderson Cancer Center, Houston, TX; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Vestan Inc., Salt Lake City, UT
| | - RHI Andtbacka
- University of Texas MD Anderson Cancer Center, Houston, TX; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Vestan Inc., Salt Lake City, UT
| | - CB Matsen
- University of Texas MD Anderson Cancer Center, Houston, TX; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Vestan Inc., Salt Lake City, UT
| |
Collapse
|
34
|
Boughey JC, Ballman KV, McCall LM, Mittendorf EA, Hunt KK. Abstract P6-09-01: Predictors of locoregional recurrence after neoadjuvant chemotherapy and surgery for node positive breast cancer: Results from ACOSOG Z1071 (Alliance). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-09-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Locoregional recurrence (LRR) is a concern after neoadjuvant chemotherapy. Absolute risk of LRR and risk factors associated with LRR among women with node positive breast cancer treated with neoadjuvant chemotherapy on ACOSOG Z1071 were examined.
Methods:
ACOSOG Z1071 (Alliance for Clinical Trials in Oncology) enrolled cT1-3, N1-2 breast cancer patients treated with neoadjuvant chemotherapy from 2009-2011. All patients underwent axillary dissection. Data was analyzed for locoregional recurrence-free survival (LR-RFS) and multivariable analysis performed to identify factors impacting locoregional recurrence.
Results:
Of 756 women enrolled, 701 patients were eligible. Median follow-up was 4.0 years (range 0.03–6.2). 39 pts (5.6%) experienced LRR (32 LRR alone and 7 LRR concurrent with metastatic disease) and 96 patients (13.7%) died. LR-RFS was lowest in patients with triple negative tumors (TNBC) (87.6% at 3 years), followed by HER2-positive tumors (94.1%) compared with Hormone Receptor (HR) positive/HER2-negative tumors (96.9%).
Residual in-breast disease was present in 57% of patients undergoing BCT and 73% of patients undergoing mastectomy (p<0.0001). LRR was higher in BCT compared to mastectomy (p=0.018), however when evaluated by subtype there was no significant difference in LRR by BCT vs mastectomy. There was no difference in LRR by clinical T stage at presentation or pathologic N stage, however LRR increased with higher pathologic T stage (p=0.006).
Overall LRR was lower in patients who achieved a pathologic complete response (pCR) across all tumor subtypes (0% in HR positive/HER2-negative, 2.1% in TNBC, 4% in HER2-positive at 3 years) than in non-pCR patients (HR=0.37, p=0.04). By tumor subtype, pCR was associated with a lower LRR in patients with TNBC (HR=0.17, p=0.019), but was not significantly different by pCR in HER2-positive (HR=0.50, p=0.31) or HR-positive/HER2-negative tumors (HR=inestimable).
In the multivariable model, factors associated with increased LRR risk were tumor subtype (TNBC and HER2-positive tumors, p<0.0001), lack of pCR in the breast (p=0.013), breast conservation surgery (p=0.018) and omission of adjuvant radiation therapy (p=0.010).
Predictors of locoregional recurrence UnivariableMultivariableVariableHR (95% CI)p-valueHR (95% CI)p-valueClinical T stageT0-T2REF0.34REF0.087T3-T41.38 (0.72-2.65) 1.87 (0.91-3.84) Tumor BiologyHR+/Her2-REF0.002REF<0.0001Her2+1.49 (0.65-3.45) 2.11 (0.89-5.00) Triple negative3.59 (1.68-7.68) 5.53 (2.53-12.13) Path CR breastNoREF0.019REF0.013Yes0.35 (0.15-0.84) 0.27 (0.09-0.76) Path CR breastNoREF0.064REF0.81Yes0.51 (0.25-1.04) 0.67 (0.29-1.59) SurgeryBCTREF0.067REF0.018Mastectomy0.55 (0.29-1.04) 0.43 (0.22-0.87) RadiationYesREF0.033REF0.010No2.18 (1.06-4.48) 2.60 (1.26-5.39)
Conclusion:
In patients with node-positive breast cancer treated with neoadjuvant chemotherapy, early LRR is higher in TNBC and HER2-positive tumors. In TNBC patients pCR is associated with lower LRR than residual disease. In this contemporary cohort of node-positive, HER2-positive tumors treated with anti-HER2 therapy, patients achieving a pCR had low LRR rate. Adjuvant radiation appears to be important for locoregional control regardless of pCR.
Citation Format: Boughey JC, Ballman KV, McCall LM, Mittendorf EA, Hunt KK. Predictors of locoregional recurrence after neoadjuvant chemotherapy and surgery for node positive breast cancer: Results from ACOSOG Z1071 (Alliance) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-09-01.
Collapse
Affiliation(s)
- JC Boughey
- Mayo Clinic, Rochester, MN; Alliance Statistics and Data Center, Rochester, MN; Alliance Statistics and Data Center, Durham, NC; University of Texas MD Anderson Cancer Center, Houston, TX
| | - KV Ballman
- Mayo Clinic, Rochester, MN; Alliance Statistics and Data Center, Rochester, MN; Alliance Statistics and Data Center, Durham, NC; University of Texas MD Anderson Cancer Center, Houston, TX
| | - LM McCall
- Mayo Clinic, Rochester, MN; Alliance Statistics and Data Center, Rochester, MN; Alliance Statistics and Data Center, Durham, NC; University of Texas MD Anderson Cancer Center, Houston, TX
| | - EA Mittendorf
- Mayo Clinic, Rochester, MN; Alliance Statistics and Data Center, Rochester, MN; Alliance Statistics and Data Center, Durham, NC; University of Texas MD Anderson Cancer Center, Houston, TX
| | - KK Hunt
- Mayo Clinic, Rochester, MN; Alliance Statistics and Data Center, Rochester, MN; Alliance Statistics and Data Center, Durham, NC; University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
35
|
Mittendorf EA, Vila J, Yi M, Chavez-MacGregor M, Chen RL, Giordano SH, Hunt KK. Abstract P6-09-17: Evaluation of a risk score based on biologic factors to enhance prognostic stratification by the American Joint Committee on Cancer (AJCC) Staging System. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-09-17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The 7th edition AJCC staging system provides prognostic information based on the anatomic extent of disease determined by the tumor size (T), lymph node status (N), and presence or absence of metastatic disease (M). Tumor biology, including grade, estrogen receptor (ER) status and HER2 status, which are known to have prognostic and predictive value, are not incorporated. This study was undertaken to evaluate a risk score that takes into account the tumor grade and other biomarkers that can be added to the current anatomic TNM staging system to improve stratification of patients with respect to disease specific survival (DSS) and overall survival (OS).
Methods: A prospectively maintained database was used to identify 3,327 patients with non-metastatic invasive breast cancer who underwent surgery as a first intervention from January 2007 through December 2013. Clinicopathologic data were recorded including: age, grade, ER status, HER2 status, and pathologic stage. Pathologic stage was determined according to the 7th edition of the AJCC staging guidelines. ER status was recorded as the percentage of cells staining positive by immunohistochemistry (IHC). Prior to 2010, tumors were classified as ER positive if there was >10% staining. A cut-off of 1% was used for patients treated after 2010, consistent with the change in American Society of Clinical Oncology (ASCO) guidelines. HER2 status was defined as positive if 3+ on immunohistochemistry or gene amplification was shown on fluorescence in situ hybridization. A risk score was calculated by assigning one point for each of the following tumor characteristics: ER-negative status, HER2 negative status and grade 3. Univariate survival analyses according to AJCC stage (I, IIA, IIB, IIIA and IIIC) and risk score (0-3) were performed for DSS and OS using the Kaplan Meier method.
Results: Median follow-up time was 5.0 years (range, 0.1 to 8.8). Five year DSS for the entire cohort was 97.9% (95% CI: 97.3%-98.4%). The distribution in risk score in the entire cohort was: risk score 0=81 (2.4%), 1=2289 (68.8%), 2=683 (20.5%), and 3= (8.3%). As shown in the table, for all AJCC stages, the 5-yr DSS and 5-yr OS varied according to risk score (p<.01).
StageRisk Scoren5-yr DSS (%)95% CI5-yr OS (%)95% CII (IA and IB)036100 9780.4-99.6 1117399.498.7-99.796.795.4-97.6 227498.896.4-00.694.691.0-06.8 311996.691.1-98.793.887.5-97.0IIA031100 96.879.2-99.5 163499.497.5-99.897.194.7-98.4 223697.593.2-99.194.188.7-97.0 39891.081.8-95.788.278.5-93.8IIB011100 100 130996.992.6-98.894.689.6-97.2 210792.983.6-97.189.380.1-94.4 34091.575.6-97.291.575.6-97.2IIIA03100 100 113498.388.2-99.891.582.6-96.0 25092.277.2-97.590.375.7-96.3 3768.621.3-91.268.621.3-91.2IIIC00 13992.272.1-98.084.463.7-93.9 21680.851.4-93.480.851.4-93.4 31033.36.3-64.633.36.2-64.6
Conclusion: The current study demonstrates that incorporating the risk score with current AJCC staging significantly improves the ability to stratify breast cancer patients with respect to DSS and OS. We recommend that the risk score be incorporated into the forthcoming revision of the AJCC staging system.
Citation Format: Mittendorf EA, Vila J, Yi M, Chavez-MacGregor M, Chen RL, Giordano SH, Hunt KK. Evaluation of a risk score based on biologic factors to enhance prognostic stratification by the American Joint Committee on Cancer (AJCC) Staging System [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-09-17.
Collapse
Affiliation(s)
- EA Mittendorf
- University of Texas MD Anderson Cancer Center, Houston, TX
| | - J Vila
- University of Texas MD Anderson Cancer Center, Houston, TX
| | - M Yi
- University of Texas MD Anderson Cancer Center, Houston, TX
| | | | - RL Chen
- University of Texas MD Anderson Cancer Center, Houston, TX
| | - SH Giordano
- University of Texas MD Anderson Cancer Center, Houston, TX
| | - KK Hunt
- University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
36
|
Alvarado M, Bold R, Gittleman M, Beitsch P, Blair S, Harmer Q, Kivilaid K, Teshome M, Thompson A, Mittendorf E, Hunt K. Abstract P2-01-11: SentimagIC: A non-inferiority trial comparing super paramagnetic iron oxide vs. Tc99 and blue dye in the detection of axillary sentinel nodes in patients with early stage breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-01-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Sentinel lymph node biopsy (SLNB), performed using radioisotope tracer with or without blue dye, is a highly accurate method for staging the axilla in early breast cancer. A radioisotope tracer with or without blue dye is the most commonly used technique for SLNB. Superparamagnetic iron oxide mapping agents detected by a handheld magnetic probe have been explored to overcome the disadvantages of the standard technique which include the short half-life, availability, handling and disposal issues for radioisotope, and the risk of allergic reactions to blue dye. Iron oxide mapping agents have been shown to be non-inferior to the standard technique in European studies. The SentimagIC trial was designed to establish the non-inferiority of a new formulation of the magnetic tracer, SiennaXP, to the combination of radioisotope and blue dye and was required to support a US regulatory submission.
Methods: Between January and December 2015, 160 patients with clinically node negative early stage breast cancer were recruited from six centers in the United States. Subjects received radioisotope injection then an intraoperative subareolar injection of SiennaXP and isosulfan blue dye prior to SLNB being performed. The sentinel node identification rate was compared between SiennaXP and the standard technique to evaluate concordance and non-inferiority.
Results: 147 procedures were completed in 147 subjects. A total of 369 histologically confirmed nodes were excised. The nodal detection rate was 94.3% (348/369) with SiennaXP and 93.5% (345/369) with the standard technique (difference 0.8%, 95% binomial confidence interval lower bound -2.1%). The per-subject detection rate was 99.3% (145/146) with SiennaXP and 98.6% (144/146) with the standard technique (one subject excluded due to not contributing any analyzable nodes). There were 22 subjects with positive SLNs, of whom 21 (95.4%) were detected by both SiennaXP and the standard tracers. In one subject, a positive node was not identified by any tracer, but was removed as clinically suspicious. The number of nodes excised per subject was 2.4 for both SiennaXP and for the standard combined technique.
Conclusion: This study showed SiennaXP is non-inferior to the standard dual technique of radioisotope and blue dye for axillary sentinel lymph node detection in early stage breast cancer and this provides a potential alternative to radioisotope and blue dye.
Citation Format: Alvarado M, Bold R, Gittleman M, Beitsch P, Blair S, Harmer Q, Kivilaid K, Teshome M, Thompson A, Mittendorf E, Hunt K. SentimagIC: A non-inferiority trial comparing super paramagnetic iron oxide vs. Tc99 and blue dye in the detection of axillary sentinel nodes in patients with early stage breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-01-11.
Collapse
Affiliation(s)
- M Alvarado
- University of California San Francisco, San Francisco, CA; University of California Davis; BreastCare Specialists Allentown; Dallas Surgical Group; University California San Diego; Endomagnetics; RCRI; University of Texas MD Anderson
| | - R Bold
- University of California San Francisco, San Francisco, CA; University of California Davis; BreastCare Specialists Allentown; Dallas Surgical Group; University California San Diego; Endomagnetics; RCRI; University of Texas MD Anderson
| | - M Gittleman
- University of California San Francisco, San Francisco, CA; University of California Davis; BreastCare Specialists Allentown; Dallas Surgical Group; University California San Diego; Endomagnetics; RCRI; University of Texas MD Anderson
| | - P Beitsch
- University of California San Francisco, San Francisco, CA; University of California Davis; BreastCare Specialists Allentown; Dallas Surgical Group; University California San Diego; Endomagnetics; RCRI; University of Texas MD Anderson
| | - S Blair
- University of California San Francisco, San Francisco, CA; University of California Davis; BreastCare Specialists Allentown; Dallas Surgical Group; University California San Diego; Endomagnetics; RCRI; University of Texas MD Anderson
| | - Q Harmer
- University of California San Francisco, San Francisco, CA; University of California Davis; BreastCare Specialists Allentown; Dallas Surgical Group; University California San Diego; Endomagnetics; RCRI; University of Texas MD Anderson
| | - K Kivilaid
- University of California San Francisco, San Francisco, CA; University of California Davis; BreastCare Specialists Allentown; Dallas Surgical Group; University California San Diego; Endomagnetics; RCRI; University of Texas MD Anderson
| | - M Teshome
- University of California San Francisco, San Francisco, CA; University of California Davis; BreastCare Specialists Allentown; Dallas Surgical Group; University California San Diego; Endomagnetics; RCRI; University of Texas MD Anderson
| | - A Thompson
- University of California San Francisco, San Francisco, CA; University of California Davis; BreastCare Specialists Allentown; Dallas Surgical Group; University California San Diego; Endomagnetics; RCRI; University of Texas MD Anderson
| | - E Mittendorf
- University of California San Francisco, San Francisco, CA; University of California Davis; BreastCare Specialists Allentown; Dallas Surgical Group; University California San Diego; Endomagnetics; RCRI; University of Texas MD Anderson
| | - K Hunt
- University of California San Francisco, San Francisco, CA; University of California Davis; BreastCare Specialists Allentown; Dallas Surgical Group; University California San Diego; Endomagnetics; RCRI; University of Texas MD Anderson
| |
Collapse
|
37
|
Lim B, Helgason T, Hess KR, Piwnica-Worms H, Yang W, Adrada BE, Rauch GM, Gilcrease M, Symmans FW, Huo L, Mittendorf EA, Thompson A, Stacy MTL, Debu T, Ueno NT. Abstract OT2-01-20: Phase IIB study of neoadjuvant panitumumab combined with carboplatin and paclitaxel (PaCT) for anthracycline-resistant triple-negative breast cancer (TNBC). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot2-01-20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Approximately 50% of patients with TNBC treatedwithstandardtaxane/anthracycline-based neoadjuvant chemotherapy (NACT)have chemo-insensitive disease (CID), i.e., residual disease burden (RCB)-II/III at the time of surgery, and 40-80% of patients develop recurrence within 3 years. Recent developments in molecular profiling have identified subsets of TNBC with distinct, targetable molecular features. We developed a clinical trial to identify and characterize CID (ARTEMIS: A Randomized, TNBC-Enrolling trial to confirm Molecular profiling Improves Survival). In ARTEMIS, patients with localized TNBC will undergo a pretreatment biopsy, then begin anthracycline-based NACT. During NACT, we use molecular profiling and response assessment to identify CID and allocate patients to alternative therapies to overcome CID. Epidermal growth factor receptor (EGFR) is overexpressed in 25-30% of TNBC. In preclinical studies, suppression of EGFR signaling has shown efficacy in controlling cancers through suppression of the stem cell population, enhanced apoptosis via MAPK/PI3K signaling, and modulation of epithelial-mesenchymal transition (EMT). Moreover, in a phase II trial of triple negative inflammatory breast cancer, neoadjuvant PaCT yielded significantly higher pathologic complete response (pCR) rates than historic control. Taken together, we hypothesize that using PaCT to suppress EGFR in TNBC will enhance the pCR rate.
OBJECTIVES: Primary objective: determine pCR and RCB-0/I rates in TNBC patients with CID given PaCT. Secondary objective: determine the benefit of using baseline genomic signatures to develop an alternative second phase of NACT.
TRIAL DESIGN AND STATISTICAL METHODS: Patients with >10% volume reduction for non-CID or <80% for CID will enroll in a biomarker-guided, experimental, nonrandomized phase II study and be given PaCT (panitumumab 2.5 mg/kg, carboplatin AUC 5, paclitaxel 80 mg/m2). Because pCR rates in pts with CID with additional cycles of taxane-based therapy are low (∼5%), a 20% response rate (RCB-0 or RCB-I) will be considered clinically meaningful. A two-stage Gehan-type design will be employed. If at least 1 of 14 patients responds, 23 more patients will be added, for a total of 37 patients. This design has a 49% chance of terminating after the first stage if the true response rate is 0.05, 23% if the rate is 0.10, 10% if the rate is 0.15, and 4% if the rate is 0.20. If accrual continues to the second stage and 37 patients are enrolled, the 95% confidence interval for a 0.20 response rate will be 0.10 to 0.35.
BRIEF ELIGIBILITY CRITERIA: Inclusion: localized TNBC; enrolled in ARTEMIS trial; adequate organ, bone marrow, and cardiac parameters; Exclusion: pregnant or lactating, known or suspected metastasis.
CORRELATIVE SCIENCE: Circulating tumor cells (CTCs) and cell free (cf) DNA in baseline and subsequent blood samples, EGFR expression (immunohistochemistry), stem cell/EMT/apoptosis marker changes in tissue and CTCs, PD-L1 glycosylation for EGFR sensitivity.
Citation Format: Lim B, Helgason T, Hess KR, Piwnica-Worms H, Yang W, Adrada BE, Rauch GM, Gilcrease M, Symmans FW, Huo L, Mittendorf EA, Thompson A, Stacy M-TL, Debu T, Ueno NT. Phase IIB study of neoadjuvant panitumumab combined with carboplatin and paclitaxel (PaCT) for anthracycline-resistant triple-negative breast cancer (TNBC) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT2-01-20.
Collapse
Affiliation(s)
- B Lim
- The University of Texas, MD Anderson Cancer Center, Houston, TX
| | - T Helgason
- The University of Texas, MD Anderson Cancer Center, Houston, TX
| | - KR Hess
- The University of Texas, MD Anderson Cancer Center, Houston, TX
| | - H Piwnica-Worms
- The University of Texas, MD Anderson Cancer Center, Houston, TX
| | - W Yang
- The University of Texas, MD Anderson Cancer Center, Houston, TX
| | - BE Adrada
- The University of Texas, MD Anderson Cancer Center, Houston, TX
| | - GM Rauch
- The University of Texas, MD Anderson Cancer Center, Houston, TX
| | - M Gilcrease
- The University of Texas, MD Anderson Cancer Center, Houston, TX
| | - FW Symmans
- The University of Texas, MD Anderson Cancer Center, Houston, TX
| | - L Huo
- The University of Texas, MD Anderson Cancer Center, Houston, TX
| | - EA Mittendorf
- The University of Texas, MD Anderson Cancer Center, Houston, TX
| | - A Thompson
- The University of Texas, MD Anderson Cancer Center, Houston, TX
| | - M-TL Stacy
- The University of Texas, MD Anderson Cancer Center, Houston, TX
| | - T Debu
- The University of Texas, MD Anderson Cancer Center, Houston, TX
| | - NT Ueno
- The University of Texas, MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
38
|
Reddy SM, Wargo JA, Reuben A, Reuben J, Woodward W, Ueno N, Mittendorf EA, Krishnamurthy S. Abstract P3-16-01: Immune characterization of inflammatory breast cancer and correlation to pathological complete response. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p3-16-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Treatment of inflammatory breast cancer (IBC) includes neoadjuvant chemotherapy (NAC) followed by mastectomy and radiation. Responses are limited however with low pathological complete response (pCR) rates and poor survival. Recent RNA expression studies suggest that activated T cell signaling pathways and immunomodulatory markers such as PD-L1 are associated with a higher pCR rate in IBC; however comprehensive studies of tumor infiltrating lymphocytes (TIL) and protein expression of immunomodulatory molecules are lacking. There is a critical need therefore to study molecular and immune determinants of therapeutic response in IBC, with the goal of identifying biomarkers and actionable strategies to improve treatment outcomes.
Methods:
Baseline core biopsies from 36 IBC patients, 22 with stage III and 14 with stage IV disease were evaluated. Of these, 21 stage III and 10 stage IV patients underwent mastectomy following NAC, the latter for palliative purposes. Tumor subtype distribution was 14 patients with HER2-/HR-, 6 with HER2+/HR-, 11 with HER2-/HR+, and 5 with HER2+/HR+ disease. TIL infiltration in the tumor stroma was quantified on H&E slides based on consensus guidelines as well as by immunohistochemistry (IHC) staining for CD8. PD-L1 expression in the TIL and invasive tumor was evaluated by IHC in tumors with >1%TIL.
Results:
Stromal TIL were found in the invasive tumor on pretreatment biopsies in 26 (72%) patients, with TIL percentages ranging from 1% to 60% (mean=11.6; sd=13.8); of note, 1 patient biopsy sample only had tumor emboli on the tissue block and therefore was not evaluable. Higher TIL infiltrate was noted in stage III versus stage IV disease (mean TIL 11.6% versus 3.5%, p=0.028). Mean TIL infiltrate was 11.5% in HER2-/HR-, 10.0% in HER2+/HR-, 10.4% in HER2+/HR+, and 3.6% in HER2-/HR+ tumors (p=NS). At mastectomy, 7/21 stage III patients and 1/10 stage IV patients achieved a pCR. Mean TIL was 13.4% in the pCR group versus 8.2% in the non-pCR group (p=0.37) CD8 and PD-L1 staining was performed on samples with >1%TIL (n=15, of which 14 samples were available for additional staining). An average of 42% of TIL stained positive for CD8 (range 10-80%). There was no significant relationship between %CD8 and pCR, stage, or receptor status. None of these 14 patients demonstrated membranous PD-L1 positivity but all had focal weak cytoplasmic staining in the lymphocytes.
Conclusions:
Differences exist in the presence of stromal TIL in distinct groups within IBC (stage III versus stage IV disease and across histologic subtypes) and may contribute to differential responses to therapy. When comparing these results to published non-IBC literature (FinHER trial), our IBC patient cohort had lower TIL infiltrate in several histologic subtypes (HER2-/HR- 11.5% vs 25%, p=0.015), HER2+/HR-(10% vs 20%, p=0.10), and HER-/HR+ disease (3.6 vs 7.5%, p=0.01); TIL was comparable for HER2+/HR+ disease. Additional studies are underway (including multiplex analysis of myeloid and lymphoid markers, T cell receptor sequencing, and molecular profiling) in pre-treatment and surgical samples to better understand mechanisms of treatment response and resistance.
Citation Format: Reddy SM, Wargo JA, Reuben A, Reuben J, Woodward W, Ueno N, Mittendorf EA, Krishnamurthy S. Immune characterization of inflammatory breast cancer and correlation to pathological complete response [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-16-01.
Collapse
Affiliation(s)
- SM Reddy
- University of Texas MD Anderson Cancer Center, Houston, TX
| | - JA Wargo
- University of Texas MD Anderson Cancer Center, Houston, TX
| | - A Reuben
- University of Texas MD Anderson Cancer Center, Houston, TX
| | - J Reuben
- University of Texas MD Anderson Cancer Center, Houston, TX
| | - W Woodward
- University of Texas MD Anderson Cancer Center, Houston, TX
| | - N Ueno
- University of Texas MD Anderson Cancer Center, Houston, TX
| | - EA Mittendorf
- University of Texas MD Anderson Cancer Center, Houston, TX
| | | |
Collapse
|
39
|
Jackson D, Peace K, Hale D, Vreeland T, Choy G, Nejadnik B, Greene J, Schneble E, Berry J, Trappey A, Hardin M, Clifton G, Herbert G, Mittendorf E, Holmes J, Peoples G. Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expression. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw378.23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
40
|
Moulder S, Litton J, Mittendorf E, Yang W, Ueno N, Hess K, Valero V, Murthy R, Ibrahim N, Lim B, Arun B, Thompson A, Piwnica-Worms H, Tripathy D, Symmans W. Improving outcomes in triple-negative breast cancer (TNBC) using molecular characterization and diagnostic imaging to identify and treat chemo-insensitive disease. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw364.76] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
Harano K, Lei X, Gonzalez-Angulo AM, Murthy RK, Valero V, Mittendorf EA, Ueno NT, Hortobagyi GN, Chavez-MacGregor M. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2016; 159:367-74. [PMID: 27522517 DOI: 10.1007/s10549-016-3933-6] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2016] [Accepted: 07/29/2016] [Indexed: 10/21/2022]
Abstract
Trastuzumab-based treatment has dramatically improved the outcomes of HER2-positive (HER2+) metastatic breast cancer (MBC) patients, with some patients achieving prolonged survival times. In this study, we aim to identify factors that are associated with long-term survival. Patients with HER2+ MBC treated with anti-HER2 target therapy were identified. Patients were grouped according to overall survival (OS) and categorized as long-term survivors (LTS, OS ≥ 5 years), or non-long-term survivors (non-LTS, OS < 5 years). Descriptive statistics and multivariable logistic regression modeling were used. A sensitivity analysis was carried out, including only patients diagnosed before 2007; therefore, 5 years of potential follow-up was possible. 1063 patients with HER2+ MBC diagnosed between 1994 and 2012 and treated with anti-HER2 therapy were identified. Among them, 154 (14.5 %) patients were categorized as LTS (median OS 92.2 months). Among LTS, 63.4 % were HR-positive and 32 % had de novo stage IV disease. Hormone receptor positivity (OR) 1.69; 95 % CI 1.17-2.44), resection of metastases (OR 2.38; 95 % CI 1.53-3.69), and primary breast surgery in patients with de novo stage IV (OR 2.88; 95 % CI 1.47-5.66) were associated with improved long-term survival. Greater number of metastatic sites (≥3 vs. 1, OR 0.41; 95 % CI 0.23-0.72) and visceral metastases (OR 0.61; 95 % CI 0.4-0.91) were associated with poor survival. Hormone receptor positivity, low burden of disease, metastasis to soft and bone tissues, and surgical management with resection of the metastatic site and the primary tumor were associated with long-term survival in patients with MBC who received anti-HER2 treatment.
Collapse
Affiliation(s)
- K Harano
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - X Lei
- Division of Cancer Prevention, Department of Health Services Research, The University of Texas MD Anderson Cancer Center, FCT9.5024, 1515 Holcombe Blvd. Unit Number: 1444, Houston, TX, 77030, USA
| | | | - R K Murthy
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - V Valero
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - E A Mittendorf
- Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - N T Ueno
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - G N Hortobagyi
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - M Chavez-MacGregor
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. .,Division of Cancer Prevention, Department of Health Services Research, The University of Texas MD Anderson Cancer Center, FCT9.5024, 1515 Holcombe Blvd. Unit Number: 1444, Houston, TX, 77030, USA.
| |
Collapse
|
42
|
Mittendorf EA, Ardavanis A, Symanowski J, Murray JL, Shumway NM, Litton JK, Hale DF, Perez SA, Anastasopoulou EA, Pistamaltzian NF, Ponniah S, Baxevanis CN, von Hofe E, Papamichail M, Peoples GE. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. Ann Oncol 2016; 27:1241-8. [PMID: 27029708 DOI: 10.1093/annonc/mdw150] [Citation(s) in RCA: 70] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2015] [Accepted: 03/19/2016] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND AE37 is the Ii-Key hybrid of the MHC class II peptide, AE36 (HER2 aa:776-790). Phase I studies showed AE37 administered with granulocyte macrophage colony-stimulating factor (GM-CSF) to be safe and highly immunogenic. A prospective, randomized, multicenter phase II adjuvant trial was conducted to evaluate the vaccine's efficacy. METHODS Clinically disease-free node-positive and high-risk node-negative breast cancer patients with tumors expressing any degree of HER2 [immunohistochemistry (IHC) 1-3+] were enrolled. Patients were randomized to AE37 + GM-CSF versus GM-CSF alone. Toxicity was monitored. Clinical recurrences were documented and disease-free survival (DFS) analyzed. RESULTS The trial enrolled 298 patients; 153 received AE37 + GM-CSF and 145 received GM-CSF alone. The groups were well matched for clinicopathologic characteristics. Toxicities have been minimal. At the time of the primary analysis, the recurrence rate in the vaccinated group was 12.4% versus 13.8% in the control group [relative risk reduction 12%, HR 0.885, 95% confidence interval (CI) 0.472-1.659, P = 0.70]. The Kaplan-Meier estimated 5-year DFS rate was 80.8% in vaccinated versus 79.5% in control patients. In planned subset analyses of patients with IHC 1+/2+ HER2-expressing tumors, 5-year DFS was 77.2% in vaccinated patients (n = 76) versus 65.7% in control patients (n = 78) (P = 0.21). In patients with triple-negative breast cancer (HER2 IHC 1+/2+ and hormone receptor negative) DFS was 77.7% in vaccinated patients (n = 25) versus 49.0% in control patients (n = 25) (P = 0.12). CONCLUSION The overall intention-to-treat analysis demonstrates no benefit to vaccination. However, the results confirm that the vaccine is safe and suggest that vaccination may have clinical benefit in patients with low HER2-expressing tumors, specifically TNBC. Further evaluation in a randomized trial enrolling TNBC patients is warranted.
Collapse
Affiliation(s)
- E A Mittendorf
- Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - A Ardavanis
- Cancer Immunology and Immunotherapy Center, St Savas Cancer Hospital, Athens, Greece
| | - J Symanowski
- Department of Cancer Biostatistics, Levine Cancer Institute, Charlotte
| | - J L Murray
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston
| | - N M Shumway
- Department of Hematology/Oncology, Brooke Army Medical Center, Ft Sam Houston Cancer Vaccine Development Laboratory, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda
| | - J K Litton
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston
| | - D F Hale
- Department of Surgery, Brooke Army Medical Center, Ft Sam Houston
| | - S A Perez
- Cancer Immunology and Immunotherapy Center, St Savas Cancer Hospital, Athens, Greece
| | - E A Anastasopoulou
- Cancer Immunology and Immunotherapy Center, St Savas Cancer Hospital, Athens, Greece
| | - N F Pistamaltzian
- Cancer Immunology and Immunotherapy Center, St Savas Cancer Hospital, Athens, Greece
| | - S Ponniah
- Cancer Vaccine Development Laboratory, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda
| | - C N Baxevanis
- Cancer Immunology and Immunotherapy Center, St Savas Cancer Hospital, Athens, Greece
| | | | - M Papamichail
- Cancer Immunology and Immunotherapy Center, St Savas Cancer Hospital, Athens, Greece
| | - G E Peoples
- Cancer Vaccine Development Program, San Antonio Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, USA
| |
Collapse
|
43
|
Ross MI, Bedrosian I, Black DM, Mittendorf EA, Caudle AS, Babiera GV, Hwang RF, Meric-Bernstam F, Grissom CB, Brulotte M, Andtbacka RHI. Abstract P3-01-09: A phase I clinical trial of VST-1001 (dilute fluorescein) in lymphatic mapping and sentinel lymph node localization in clinically node negative breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-01-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Combined use of a radiocolloid and a vital blue dye is recommended for accurate lymphatic mapping and sentinel lymph node (SLN) identification. However, vital blue dyes can cause tattooing, skin necrosis and allergic reactions. Hence, there is a great need for new lymphatic mapping agents. Here we describe the novel use of VST-1001 (dilute fluorescein) and direct visualization devices in lymphatic mapping and SLN identification.
Methods: A prospective, non randomized, single arm, open label, single dose, dose-finding Phase I clinical trial in patients (pts) with high-grade DCIS and clinical stage I/II breast cancer eligible for SLN biopsy was performed. All pts had SLN localization with technetium-99m-sulfur colloid (Tc99mSC) and intraoperative lymphatic mapping with VST-1001 injected peritumorally, periareolarly, and/or intradermally. SLN radioactivity was identified with a gamma probe, and VST-1001 fluorescence was induced by light emitting diodes and detected as a yellowish-green fluorescence in the visible light range with notch filter spectacles. The primary endpoints were safety, ability of VST 1001 to localize lymph nodes, and the optimal dose of VST-1001. SLN concordance of Tc99mSC radioactivity and VST-1001 fluorescence was also assessed.
Results: Fifteen women with a median age of 60 yrs (range, 43-80) were enrolled. In cohort 1, 5 pts received 0.01% VST-1001. All patients had at least 1 SLN that was fluorescent and radioactive. A total of 22 SLNs were identified, many with faint fluorescence. Per protocol, the dose of VST-1001 was increased, and in cohort 2, 10 patients received 0.1% VST-1001. All 10 (100%) pts in cohort 2 had at least 1 SLN that was fluorescent and radioactive. Of a total of 24 SLNs identified, 20 (83%) were fluorescent and radioactive, 2 (8%) were radioactive only, and 2 (8%) were fluorescent only. Four SLNs in 3 patients contained micrometastatic breast cancer; all 4 SLNs were radioactive and fluorescent. There were no adverse events related to VST-1001. A Phase II clinical trial is currently accruing.
Conclusions: VST-1001 safely localized lymph nodes in breast cancer. VST-1001 was able to localize lymph nodes that were not radioactive and had a high concordance with Tc99mSC. VST-1001 may be a novel alternative to vital blue dyes in lymphatic mapping and lymph node localization.
Citation Format: Ross MI, Bedrosian I, Black DM, Mittendorf EA, Caudle AS, Babiera GV, Hwang RF, Meric-Bernstam F, Grissom CB, Brulotte M, Andtbacka RHI. A phase I clinical trial of VST-1001 (dilute fluorescein) in lymphatic mapping and sentinel lymph node localization in clinically node negative breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-01-09.
Collapse
Affiliation(s)
- MI Ross
- University of Texas MD Anderson Cancer Center, Houston, TX; Vestan Inc., Salt Lake City, UT
| | - I Bedrosian
- University of Texas MD Anderson Cancer Center, Houston, TX; Vestan Inc., Salt Lake City, UT
| | - DM Black
- University of Texas MD Anderson Cancer Center, Houston, TX; Vestan Inc., Salt Lake City, UT
| | - EA Mittendorf
- University of Texas MD Anderson Cancer Center, Houston, TX; Vestan Inc., Salt Lake City, UT
| | - AS Caudle
- University of Texas MD Anderson Cancer Center, Houston, TX; Vestan Inc., Salt Lake City, UT
| | - GV Babiera
- University of Texas MD Anderson Cancer Center, Houston, TX; Vestan Inc., Salt Lake City, UT
| | - RF Hwang
- University of Texas MD Anderson Cancer Center, Houston, TX; Vestan Inc., Salt Lake City, UT
| | - F Meric-Bernstam
- University of Texas MD Anderson Cancer Center, Houston, TX; Vestan Inc., Salt Lake City, UT
| | - CB Grissom
- University of Texas MD Anderson Cancer Center, Houston, TX; Vestan Inc., Salt Lake City, UT
| | - M Brulotte
- University of Texas MD Anderson Cancer Center, Houston, TX; Vestan Inc., Salt Lake City, UT
| | - RHI Andtbacka
- University of Texas MD Anderson Cancer Center, Houston, TX; Vestan Inc., Salt Lake City, UT
| |
Collapse
|
44
|
Mitri ZI, Ueno NT, Yang W, Valero V, Litton JK, Murthy RK, Ibrahim NK, Arun BK, Mittendorf EA, Hunt KK, Meric-Bernstam F, Thompson A, Piwnica-Worms H, Tripathy D, Symmans F, Moulder-Thompson S. Abstract OT2-03-03: Women's triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer using molecular triaging and diagnostic imaging to guide neoadjuvant therapy. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-ot2-03-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND:
In triple negative breast cancer (TNBC), pathologic compete response/residual cancer burden-0 (pCR/RCB-0) or minimal residual disease (RCB-I) following neoadjuvant chemotherapy (NACT) is associated with a good prognosis. This is in contrast to extensive residual disease (RCB-II-III) which carries approximately a 50% chance of recurrence. These patients have a particularly poor prognosis as there are currently no targeted agents to salvage chemoresistant disease. It is important to predict pCR in order to direct responsive disease toward standard NACT and non-responsive disease (NRD) to therapy on clinical trials.
TRIAL DESIGN:
The use of genomic signatures (JAMA, 2011; 305:1873-81) and imaging to predict response to NACT will be validated, and the clinical impact of selecting patients with predicted NRD for targeted therapy on clinical trial will be determined. Patients will undergo primary tumor biopsy for molecular profiling and will be randomized 2:1 to know the results versus not (control). Following that, all patients will receive 4 cycles of anthracycline-based NACT, with imaging used for response assessment. Patients with molecular/imaging criteria for NRD will be offered enrollment on a clinical trial based upon molecular profiling or based upon physician/patient choice (control).
INCLUSION CRITERIA:
Tumor size ≥1.5 cm diameter; TNBC by standard assays; ≥18 years of age; LVEF ≥50%; adequate organ and bone marrow function
EXCLUSION CRITERIA:
Stage IV disease; invasive cancer within 5 years; excisional biopsy of the primary tumor; features that limit response assessment by imaging; unfit for taxane and/or antracycline regimens; prior anthracycline therapy; ≥grade II neuropathy; Zubrod performance status of ≥2; history of serious cardiac events
PRIMARY AIM:
- Prospectively determine the impact of a molecular diagnostic/imaging platform in patients with localized invasive TNBC
SECONDARY AIMS:
- Compare rates of clinical trial enrollment
- Evaluate disease free survival in the experimental arms compared to control standard NACT
- Perform integrated biomarker analyses and identify therapeutic targets for resistant disease
STATISTICAL METHODS:
A maximum of 360 patients will be randomized (2:1)using a group sequential design with one-sided O'Brien-Fleming boundaries, with two equally spaced binding interim tests for futility and superiority and one final test, having an overall Type I error .05 and power .80 to detect an improvement in pCR/RCB-I from 50% to 64%.
Citation Format: Mitri ZI, Ueno NT, Yang W, Valero V, Litton JK, Murthy RK, Ibrahim NK, Arun BK, Mittendorf EA, Hunt KK, Meric-Bernstam F, Thompson A, Piwnica-Worms H, Tripathy D, Symmans F, Moulder-Thompson S. Women's triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer using molecular triaging and diagnostic imaging to guide neoadjuvant therapy. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr OT2-03-03.
Collapse
Affiliation(s)
- ZI Mitri
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - NT Ueno
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - W Yang
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - V Valero
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - JK Litton
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - RK Murthy
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - NK Ibrahim
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - BK Arun
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - EA Mittendorf
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - KK Hunt
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | - A Thompson
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - H Piwnica-Worms
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - D Tripathy
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - F Symmans
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | | |
Collapse
|
45
|
Mittendorf EA, Dogan B, Morgan R, Chargin A, Wu Y, Cornett-Risher S, Shults K. Abstract P1-01-17: Integrative pathology: Analysis of cellular multiplex technology to detect proteomic, genomic and DNA data from fine needle aspiration biopsy specimens. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-01-17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: An integrative system capable of detecting proteomic, genomic and DNA content from cell isolates obtained by fine needle aspiration (FNA) biopsy may offer distinct advantages in diagnosing breast cancer and monitoring response to therapy. Cellular Multiplex™ is such a system. An initial pilot study evaluating this technology established a series of variables that could separate normal from cancerous elements using cells obtained from an FNA performed on excised tumors and reduction mammoplasty specimens. In order for the technology to be clinically relevant, it must perform robustly on intact tumors. The current study was therefore undertaken to validate Cellular Multiplex™ on cells obtained by FNA performed on intact tumor at the time of diagnosis.
Methods: Patients undergoing lumpectomy requiring either needle or 125I seed localization were identified. FNA was performed on intact tumor (A samples) at the time of radiographic localization prior to lumpectomy and repeated on the excised tumor (B samples). Cells obtained by FNA were placed in a proprietary fixative then hybridized and stained to detect multiple mRNA and protein targets along with DNA content. Estrogen receptor, progesterone receptor and HER2 were included in the panel of targets and compared to the routine clinical pathology report. Cell morphology was assessed by mean corpuscular volume. Samples were analyzed using an EC800 (Sony Biotechnology, San Jose, CA) and the results from matched A and B samples were compared using the Mann-Whitney Wilcoxson Rank Sum test. The study is designed to enroll 50 patients. Here we report an analysis of the first 9 cases.
Results: The cell number obtained from the excised tumors were 3-4 times greater (median to median) than obtained from the intact tumor. There was no statistical difference in the expression of the 2 mRNA targets, 8 protein targets, DNA content and cell morphology between the A and B samples. The parameters derived from Cellular Multiplex matched the standard pathologic features reported on the clinical pathology report in 8 of 9 cases. In the one discrepant case, Cellular Multiplexing detected ER positive cells in a case where standard pathologic evaluation with immunohistochemistry reported the tumor to be estrogen receptor negative.
Conclusions: This interim analysis demonstrates that the Cellular Multiplex technology is working well using cells obtained by FNA performed on intact tumors with readouts matching those obtained from excised specimens. If confirmed in the remaining patients, these data suggest that this technology will be applicable for the evaluation of intact tumors thereby making it relevant for multiple clinical indications including diagnosis and monitoring response to neoadjuvant therapy.
Citation Format: Mittendorf EA, Dogan B, Morgan R, Chargin A, Wu Y, Cornett-Risher S, Shults K. Integrative pathology: Analysis of cellular multiplex technology to detect proteomic, genomic and DNA data from fine needle aspiration biopsy specimens. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-01-17.
Collapse
Affiliation(s)
- EA Mittendorf
- The University of Texas MD Anderson Cancer Center, Houston, TX; Penfold-Patterson Research Institute, Frankfort, MI
| | - B Dogan
- The University of Texas MD Anderson Cancer Center, Houston, TX; Penfold-Patterson Research Institute, Frankfort, MI
| | - R Morgan
- The University of Texas MD Anderson Cancer Center, Houston, TX; Penfold-Patterson Research Institute, Frankfort, MI
| | - A Chargin
- The University of Texas MD Anderson Cancer Center, Houston, TX; Penfold-Patterson Research Institute, Frankfort, MI
| | - Y Wu
- The University of Texas MD Anderson Cancer Center, Houston, TX; Penfold-Patterson Research Institute, Frankfort, MI
| | - S Cornett-Risher
- The University of Texas MD Anderson Cancer Center, Houston, TX; Penfold-Patterson Research Institute, Frankfort, MI
| | - K Shults
- The University of Texas MD Anderson Cancer Center, Houston, TX; Penfold-Patterson Research Institute, Frankfort, MI
| |
Collapse
|
46
|
Mittendorf EA, Vila J, Tucker SL, Chavez-MacGregor M, Smith BD, Symmans WF, Sahin AA, Hortobagyi GN, Hunt KK. Abstract P5-08-04: Bioscore: A novel staging system for breast cancer patients receiving neoadjuvant chemotherapy. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-08-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: We previously described a novel breast cancer staging system, the CPS+EG score, which incorporates pretreatment clinical stage, post-treatment pathologic stage, estrogen receptor (ER) status and nuclear grade to create an ordinal scale that is predictive of disease-specific survival (DSS) after receipt of neoadjuvant chemotherapy. The prior work predated (1997-2005) routine use of trastuzumab for patients with HER2+ disease. The current study was undertaken to update the staging system with a more contemporary cohort of patients to include patients with HER2+ disease receiving trastuzumab. The impact of using 1% as the cutoff for ER-positivity was also assessed.
Methods: A cohort of 2377 patients treated with neoadjuvant chemotherapy from 2005-2012 was identified. Clinicopathologic characteristics, treatment regimens and patient outcomes were recorded. Patient scores were computed using two versions of the CPS+EG staging system with ER status categorized as positive if >10% or if >1%. Fits of the Cox proportional hazards (PH) model for the two sets of prognostic scores were compared using the Akaike Information Criterion (AIC). HER2 status was then added to the model and the likelihood ratio test was used to determine the improvement in fit.
Results: Median follow-up time was 4.2 years (range, 0.5 to 11.7). Five year DSS was 89% (95% CI: 87%-90%). This cohort validated our previous finding that the CPS+EG score facilitates more refined categorization into prognostic subgroups than initial clinical or final pathologic stage alone (table). The AIC demonstrated that the CPS+EG model fits were nearly identical for ER status categorized using either cutoff, though the fit was slightly better for the >1% cutoff. There were 591 HER2+ patients included; all of them received trastuzumab-based chemotherapy. The improvement in the fit of the model when HER2 status was added was highly significant (p=0.00005) and incorporation of HER2 into the CPS+EG staging system by adding one additional point for HER2-negative status defined the bioscore (table) which again stratified patients with respect to prognosis.
Conclusion: The current study demonstrates a novel bioscore that significantly improves a previously validated prognostic score in patients receiving neoadjuvant chemotherapy and allows the staging system to be applied to patients with HER2+ disease. We recommend that biologic markers and response to treatment be incorporated into the forthcoming revision of the AJCC staging system.
Clinical Stage5-yr DSS (95%CI)Pathologic Stage5-yr DSS (95%CI)CPS+EG Score (1% cutoff for ER+)5-yr DSS (95%CI)Bioscore5-yr DSS (95%CI)0 097% (95-98%)098% (92-100%)097% (78-10)%)IA96% (75-99%)IA95% (92-97%)198% (96-99%)199% (95-100%)IIA96% (94-97%)IB90% (76-98%)294% (91-95%)297% (95-98%)IIB90% (87-92%)IIA91% (87-94%)387% (84-90%)393% (90-95%)IIIA85% (80-89%)IIB86% (81-90%)475% (69-80%)486% (82-89%)IIIB78% (70-85%)IIIA80% (75-84%)552% (40-63%)571% (64-77%)IIIC76% (70-81%)IIIB64% (42-80%)60648% (35-60%) IIIC64% (55-72%) 70
Citation Format: Mittendorf EA, Vila J, Tucker SL, Chavez-MacGregor M, Smith BD, Symmans WF, Sahin AA, Hortobagyi GN, Hunt KK. Bioscore: A novel staging system for breast cancer patients receiving neoadjuvant chemotherapy. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-08-04.
Collapse
Affiliation(s)
- EA Mittendorf
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - J Vila
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - SL Tucker
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | - BD Smith
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - WF Symmans
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - AA Sahin
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - GN Hortobagyi
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - KK Hunt
- The University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
47
|
Mittendorf EA, Clifton GT, Holmes JP, Schneble E, van Echo D, Ponniah S, Peoples GE. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol 2014; 25:1735-1742. [PMID: 24907636 PMCID: PMC4143091 DOI: 10.1093/annonc/mdu211] [Citation(s) in RCA: 177] [Impact Index Per Article: 17.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2014] [Revised: 05/24/2014] [Accepted: 05/27/2014] [Indexed: 01/07/2023] Open
Abstract
BACKGROUND E75 (nelipepimut-S) is a human leukocyte antigen (HLA)-A2/A3-restricted immunogenic peptide derived from the HER2 protein. We have conducted phase I/II clinical trials vaccinating breast cancer patients with nelipepimut-S and granulocyte-macrophage colony-stimulating factor (GM-CSF) in the adjuvant setting to prevent disease recurrence. All patients have completed 60 months follow-up, and here, we report the final analyses. PATIENTS AND METHODS The studies were conducted as dose escalation/schedule optimization trials enrolling node-positive and high-risk node-negative patients with tumors expressing any degree of HER2 (immunohistochemistry 1-3+). HLA-A2/3+ patients were vaccinated; others were followed prospectively as controls. Local and systemic toxicity was monitored. Clinical recurrences were documented, and disease-free survival (DFS) was analyzed by Kaplan-Meier curves; groups were compared using log-rank tests. RESULTS Of 195 enrolled patients, 187 were assessable: 108 (57.8%) in the vaccinated group (VG) and 79 (42.2%) in the control group (CG). The groups were well matched for clinicopathologic characteristics. Toxicities were minimal. Five-year DFS was 89.7% in the VG versus 80.2% in the CG (P = 0.08). Due to trial design, 65% of patients received less than the optimal vaccine dose. Five-year DFS was 94.6% in optimally dosed patients (P = 0.05 versus the CG) and 87.1% in suboptimally dosed patients. A voluntary booster program was initiated, and among the 21 patients that were optimally boosted, there was only one recurrence (DFS = 95.2%). CONCLUSION The E75 vaccine is safe and appears to have clinical efficacy. A phase III trial evaluating the optimal dose and including booster inoculations has been initiated. CLINICAL TRIALS NCT00841399, NCT00584789.
Collapse
Affiliation(s)
- E A Mittendorf
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston
| | - G T Clifton
- Blanchfield Army Community Hospital, Fort Campbell
| | - J P Holmes
- Redwood Regional Medical Group, Santa Rosa
| | - E Schneble
- Department of Surgery, Brooke Army Medical Center, Ft Sam Houston
| | - D van Echo
- Department of Hematology Oncology, Walter Reed Army Medical Center, Washington
| | - S Ponniah
- Department of Surgery, Cancer Vaccine Development Program, United States Military Cancer Institute, Uniformed Services University of the Health Sciences, Bethesda, USA
| | - G E Peoples
- Department of Surgery, Brooke Army Medical Center, Ft Sam Houston; Department of Surgery, Cancer Vaccine Development Program, United States Military Cancer Institute, Uniformed Services University of the Health Sciences, Bethesda, USA.
| |
Collapse
|
48
|
Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, Bedrosian I, Buzdar AU, Symmans WF, Crow JR, Bender M, Shah RR, Hortobagyi GN, Hunt KK. Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann Oncol 2014; 25:1004-11. [PMID: 24562447 DOI: 10.1093/annonc/mdu053] [Citation(s) in RCA: 151] [Impact Index Per Article: 15.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
BACKGROUND Guidelines for the use of chemotherapy and endocrine therapy recently recommended that estrogen receptor (ER) status be considered positive if ≥1% of tumor cells demonstrate positive nuclear staining by immunohistochemistry. In clinical practice, a range of thresholds are used; a common one is 10% positivity. Data addressing the optimal threshold with regard to the efficacy of endocrine therapy are lacking. In this study, we compared patient, tumor, treatment and survival differences among breast cancer patients using ER-positivity thresholds of 1% and 10%. METHODS The study population consisted of patients with primary breast carcinoma treated at our center from January 1990 to December 2011 and whose records included complete data on ER status. Patients were separated into three groups: ≥10% positive staining for ER (ER-positive ≥10%), 1%-9% positive staining for ER (ER-positive 1%-9%) and <1% positive staining (ER-negative). RESULTS Of 9639 patients included, 80.5% had tumors that were ER-positive ≥10%, 2.6% had tumors that were ER-positive 1%-9% and 16.9% had tumors that were ER-negative. Patients with ER-positive 1%-9% tumors were younger with more advanced disease compared with patients with ER-positive ≥10% tumors. At a median follow-up of 5.1 years, patients with ER-positive 1%-9% tumors had worse survival rates than did patients with ER-positive ≥10% tumors, with and without adjustment for clinical stage and grade. Survival rates did not differ significantly between patients with ER-positive 1%-9% and ER-negative tumors. CONCLUSIONS Patients with tumors that are ER-positive 1%-9% have clinical and pathologic characteristics different from those with tumors that are ER-positive ≥10%. Similar to patients with ER-negative tumors, those with ER-positive 1%-9% disease do not appear to benefit from endocrine therapy; further study of its clinical benefit in this group is warranted. Also, there is a need to better define which patients of this group belong to basal or luminal subtypes.
Collapse
Affiliation(s)
- M Yi
- Department of Surgical Oncology
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Berry JS, Trappey AF, Vreeland TJ, Schneble EJ, Clifton GT, Hale DF, Sears AK, Ponniah S, Shumway NM, Mittendorf EA, Peoples GE. Abstract P4-13-02: Preliminary results for the phase 1 trial of a dual HER2 peptide cancer vaccine in breast and ovarian cancer patients. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-13-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: HER2 is a commonly expressed tumor-associated antigen in breast (BrCa) and ovarian cancer (OvCa) and, therefore, an attractive target for immunotherapy. We have investigated HER2-derived peptides as vaccines mixed with GM-CSF to include GP2 (a HLA-A2 and HLA-A3 restricted, CD8+ eliciting epitope) and AE37 (a HLA unrestricted, MHC class II, CD4+ eliciting epitope). Both peptide vaccines (PV) have shown clinical promise individually. There is clear rationale for combining GP2 and AE37 to elicit a more robust immune response (IR) of both CD4+ and CD8+ T cells. Here, we summarize initial toxicity (tox) and in vivo IR data from a phase 1 trial of the combined PV.
METHODS: The trial is being performed as a five cohort, 3+3 dose-escalation, safety trial. Clinically disease-free, HLA-A2+ and A3+, BrCa and OvCa patients with tumors expressing any level of HER2 (IHC 1-3+) and who have completed standard-of-care therapy are accrued. In the first cohort, three patients received six, monthly intradermal inoculations (R1-R6) of 100mcg of AE37, 100mcg of GP2, and 125mcg of GM-CSF or 100:100:125. The second cohort received 250mcg of AE37, 100mcg of GP2, and 125mcg of GM-CSF or 250:100:125. Three additional cohorts were vaccinated: 250:250:125, 500:250:125, and 500:500:125. Toxicity was graded 48-72 hours post vaccination using NCI Toxicity Criteria v4.0. After each inoculation, local reactions (LR) are measured via the sensitive ballpoint pen method and reported as the orthogonal mean (OM). IR is assessed in vivo by delayed type hypersensitivity (DTH) reactions with separate intradermal inoculations of AE37, AE36, and GP2 antigens, measured both pre-vaccination (R0) and after the vaccine series (R6) via the sensitive ballpoint pen method, and reported as the OM. Means were compared using paired t-tests.
RESULTS: 28 patients enrolled; 8 withdrew consent, 1 recurred prior to completing R6, 3 had an intercurrent illness, 14 patients completed R1-R6, and the vaccine series is ongoing in 2 patients. Six patients did not receive any inoculations and, therefore, are not included in this safety analysis. In 22 patients, the vaccine was well tolerated (max local tox: 23% Grade (Gr) 1, 73% Gr 2, 4% Gr 3; max systemic tox: 14% Gr 0, 50% Gr 1, 36% Gr 2). No dose-limiting toxicity was observed. For the 14 patients who completed the VS, the median age was 51(35-83). Breast tumor size was 3.3±1.1cm and ovarian tumor size was 10.0±2.3cm. Compared to GP2 LR at R1 (15.5±4.1mm), LR increased at R2 (31.7±5.9mm), R3 (42.9±7.4mm), R4 (35.3±7.3mm), R5 (45.0±9.9mm), and R6 (25.9±6.7mm, p = 0.17). Compared to the AE37 LR at R1 (18.5±3.8mm), LR increased at R2 (37.3±6.7mm), R3 (36.4±4.6mm), R4 (42.2±5.9mm), R5 (46.0±8.9mm), and R6 (36.2±6.6mm). Unless stated, all LR p-values < 0.05. After the VS, AE37 DTH increased from 0.0±0.0mm to 19.6±6.7mm (p<0.01), AE36 DTH increased from 0.0±0.0mm to 10.3±3.9mm (p<0.01), and GP2 DTH reactions increased from 0.3±0.2mm to 4.1±2.0mm (p = 0.056).
CONCLUSIONS: Initial results from a phase I trial of a vaccine combining GP2 and AE37 peptides show that dual administration of the peptides is well tolerated at all tested dosing levels. Additionally, the combination is capable of stimulating strong peptide-specific in vivo immune responses. Continued testing of this vaccination strategy is underway.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-13-02.
Collapse
Affiliation(s)
- JS Berry
- San Antonio Military Medical Center, Fort Sam Houston, TX; MD Anderson Cancer Center, Houston, TX
| | - AF Trappey
- San Antonio Military Medical Center, Fort Sam Houston, TX; MD Anderson Cancer Center, Houston, TX
| | - TJ Vreeland
- San Antonio Military Medical Center, Fort Sam Houston, TX; MD Anderson Cancer Center, Houston, TX
| | - EJ Schneble
- San Antonio Military Medical Center, Fort Sam Houston, TX; MD Anderson Cancer Center, Houston, TX
| | - GT Clifton
- San Antonio Military Medical Center, Fort Sam Houston, TX; MD Anderson Cancer Center, Houston, TX
| | - DF Hale
- San Antonio Military Medical Center, Fort Sam Houston, TX; MD Anderson Cancer Center, Houston, TX
| | - AK Sears
- San Antonio Military Medical Center, Fort Sam Houston, TX; MD Anderson Cancer Center, Houston, TX
| | - S Ponniah
- San Antonio Military Medical Center, Fort Sam Houston, TX; MD Anderson Cancer Center, Houston, TX
| | - NM Shumway
- San Antonio Military Medical Center, Fort Sam Houston, TX; MD Anderson Cancer Center, Houston, TX
| | - EA Mittendorf
- San Antonio Military Medical Center, Fort Sam Houston, TX; MD Anderson Cancer Center, Houston, TX
| | - GE Peoples
- San Antonio Military Medical Center, Fort Sam Houston, TX; MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
50
|
Trappey AF, Berry JS, Vreeland TJ, Guy CT, Diane HF, Alan SK, Erika SJ, Ferrise L, Shumway NM, Papamichail M, Perez SA, Ponniah S, Mittendorf EA, Peoples GE. Abstract P4-13-05: HLA-A2 is not a prognostic indicator in breast cancer: Implications for cancer vaccine trials. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-13-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
Peptide-based cancer vaccines require presentation by a specific HLA molecule. HLA-A2 is the most common class I allele in the US (40-50% of the population) and, therefore, the most commonly targeted. Our group has been investigating HER2-derived peptide vaccines administered in the adjuvant setting to high risk breast cancer patients in order to prevent disease recurrence. This study was undertaken to compare known prognostic factors and disease-free survival (DFS) in control HLA-A2+ and HLA-A2- patients in order to better define these populations for future trial design.
Methods
Our group is currently enrolling patients in a phase II trial evaluating the HER2-derived peptide vaccines, AE37 (MHC Class II, HLA-non-restricted epitope) and GP2 (MHC Class I, HLA-A2+ restricted epitope). The studies are enrolling high-risk, disease-free breast cancer patients with any level of HER2 expression (IHC 1+, 2+ or 3+) after completion of standard of care therapy. Patients are HLA-typed. HLA-A2+ patients are randomized to GP2+GM-CSF or GM-CSF alone. HLA-A2- patients are randomized to AE37+GM-CSF or GM-CSF alone. Demographics between groups are compared using chi squared or fisher exact as appropriate. DFS is compared using log rank.
Results
Thus far, 407 patients have been enrolled to the study (181 HLA-A2+ and 226 HLA-A2-). Demographics are shown in Table 1.
Table 1. Demographics (all) A2+A2-pn181226 Age (median)51500.47Node Positive62%66%0.46Grade 354%54%0.99Tumor >/ = 2 cm59%64%0.23ER/PR Negative36%38%0.59HER2 Overexpression55%51%0.39Triple Negative13%15%0.52
There are no differences between groups with respect to age, node positivity, grade, tumor size, ER/PR status, HER2 over-expression, or triple negative breast cancer. Of those enrolled, 83 HLA-A2+ patients and 109 HLA-A2- patients have been randomized to the control groups. Within the control group, there are no differences between the HLA-A2+ and HLA-A2- patients regarding age, node positivity, grade, tumor size, ER/PR status, HER2 over-expression, or triple negative breast cancer (Table 2).
With a median follow-up of 30 months, DFS is similar between A2+ and A2- control patients (83% v. 80%, p = 0.93).
Conclusions
Baseline clinico-pathologic factors are similar between HLA-A2+ and HLA-A2- breast cancer patients with no correlations to known prognostic factors. Well-matched blinded control patients treated only with GM-CSF demonstrate no differences in DFS between HLA-A2+ and HLA-A2- patients. Therefore, it does not appear that HLA-A2 status is a prognostic factor in breast cancer, and HLA-A2+ and HLA-A2- patients should be comparable in peptide-based breast cancer vaccine trials.
Table 2. Demographics (Control Group Only) A2+A2-pn83109 Age (median)51510.75Node Positive65%64%0.99Grade 359%57%0.76Tumor >/ =59%71%0.08ER/PR Negative36%38%0.84HER2 Overexpression55%46%0.19Triple Negative11%16%0.34
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-13-05.
Collapse
Affiliation(s)
- AF Trappey
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| | - JS Berry
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| | - TJ Vreeland
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| | - CT Guy
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| | - HF Diane
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| | - SK Alan
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| | - SJ Erika
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| | - L Ferrise
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| | - NM Shumway
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| | - M Papamichail
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| | - SA Perez
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| | - S Ponniah
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| | - EA Mittendorf
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| | - GE Peoples
- San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
| |
Collapse
|